STOCK TITAN

Functional Brands nine-month loss widens to $10.3M

Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Functional Brands Inc. (MEHA) reported nine-month revenue of $5,161,125, compared with $5,116,963 a year earlier, while net loss widened to $10,335,792 from $93,837. Operating activities used $1,018,212 of cash, versus providing $1,478,358; cash was $231,900 and the working capital deficit was $5,804,557 at September 30, 2026.

The company ceased HT Naturals and its hemp-based consumer products business on March 31, leaving the Kirkman business as its continuing operation. Failure to begin Series C mandatory redemptions and the June 16 Nasdaq delisting triggered defaults under Series C and senior secured convertible notes. The Series C stated value of $2,764,000 remains subject to redemption; default terms include 24% annual Series C dividends and note interest, note obligations at 125% of otherwise outstanding amounts, and a $5,000 monthly monitoring fee. No holder had accelerated as of the report date. Management says substantial doubt about continuing as a going concern remains and concluded its plans were not probable of effective implementation or mitigation. BullionFX terminated a proposed acquisition with expected consideration of approximately $142.9 million in preferred stock, subject to valuation and verification.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

4 major · 5 points

How the balance works

Positive

  • None.

Negative

  • Major pointSubstantial doubt remains; September 30 cash was $231,900.
  • Major pointDefaults impose 24% rates, 125% note obligations and $5,000 monthly fees.
  • Major pointNet loss reached $10,335,792, versus $93,837 in 2025.
  • Major pointNasdaq delisting shifted MEHA common-stock trading to OTC on June 16, 2026.
  • Moderate pointOperating cash flow was $1,018,212 used, versus $1,478,358 provided.

Filing Explained

At September 30, 2026, common shares outstanding were 64,921,095, and default conversion pricing was tied to a recent trading low.

At September 30, 2026, Functional Brands had 64,921,095 common shares outstanding, up from 18,704,649 at December 31, 2025; the higher share count reduces existing holders’ percentage ownership. The Series C and notes remained in default, and no holder had accelerated them as of the report date.

The March 9, 2026 exchange issued Series C shares and senior secured notes as partial consideration for cancelling Series A and B preferred shares; the company says those issuances brought in no new cash proceeds.

After default, the Series C and notes’ conversion price became 85% of the lowest trading price over the preceding ten trading days, replacing the fixed conversion pricing for that period.

Revenue $5,161,125 Nine months ended September 30, 2026; $5,116,963 in 2025, a reported increase of 1%.
Net loss $10,335,792 Nine months ended September 30, 2026; net loss was $93,837 in 2025.
Operating cash flow $1,018,212 used Nine months ended September 30, 2026; $1,478,358 provided in 2025.
Cash $231,900 Balance as of September 30, 2026.
Working capital deficit $5,804,557 As of September 30, 2026.
Series C stated value subject to mandatory redemption $2,764,000 Outstanding stated value as of September 30, 2026.
Default interest and Series C dividend rate 24% per annum Rates applicable following the events of default.
Default note obligations 125% of otherwise outstanding amounts Default-premium provision applicable to the Notes.
going concern financial
"substantial doubt about the Company’s ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
mandatory redemption financial
"failure to commence the Series C mandatory redemption"
Mandatory redemption is a contract clause that forces an issuer to buy back a security—such as a bond, preferred share, or convertible—under specified conditions or at scheduled times. For investors it matters because it determines when and how they will get their principal or liquidation value returned, affects the timing of income, and can change the total number of outstanding securities, similar to a store being required to repurchase a product on a set schedule.
Event of Default financial
"constitutes an Event of Default under the Series C"
An event of default is a specific breach of a loan or bond agreement—such as missed payments or breaking agreed rules—that gives lenders the legal right to act, for example by demanding immediate repayment, seizing collateral, or accelerating other obligations. For investors, it’s a red flag because it can sharply reduce a company’s ability to operate or raise money, like a car lender repossessing a vehicle after missed payments, and often leads to falling share or bond prices.
default premium financial
"default-rate interest and a default premium apply"
Default premium is the extra return investors demand for holding a bond or loan that could fail to pay back principal or interest, above a safe benchmark like government debt. It matters because a rising premium signals higher perceived risk of loss and raises borrowing costs for issuers, much like a higher insurance price reflects greater chance of a claim — affecting investment returns and company financing decisions.
alternate conversion price financial
"the conversion price applicable to the Series C and the Notes became the alternate conversion price"
Level 3 technical
"classified within Level 3 of the fair value hierarchy"
Level 3 describes the lowest-confidence category in the accounting “fair value” hierarchy, covering assets or liabilities whose prices are not observable in the market and must be estimated using judgment and internal models. For investors, Level 3 items matter because they can introduce greater uncertainty and potential valuation swings—like valuing a unique antique versus checking a price tag on a supermarket shelf—so they signal higher model risk and lower liquidity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue and net loss did MEHA report for the first nine months of 2026?

MEHA reported revenue of $5,161,125 and net loss of $10,335,792 for the nine months ended September 30, 2026. The comparable 2025 amounts were $5,116,963 in revenue and $93,837 in net loss.

What default terms apply to MEHA’s Series C and convertible notes?

The defaults raised the Series C dividend rate and note interest rate to 24% per annum, increased outstanding note obligations to 125% of otherwise outstanding amounts, and imposed a $5,000 monthly monitoring fee. As of the report date, no holder had accelerated the Notes or Series C.

Did MEHA complete the proposed BullionFX asset acquisition?

No. BullionFX terminated the May 11, 2026 binding letter of intent on June 29, 2026. The proposal covered certain intellectual property and related assets, with expected consideration of approximately $142.9 million in convertible preferred stock, subject to independent third-party valuation and verification.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
NONE http://fasb.org/srt/2026#ChiefExecutiveOfficerMember 1 1 0001837254 false Q3 --12-31 0001837254 2026-07-01 2026-09-30 0001837254 2026-01-01 2026-09-30 0001837254 2026-07-14 0001837254 meha:TrailerParkBoysIncorporatedMember 2026-09-30 0001837254 2026-09-30 0001837254 us-gaap:PreferredStockMember 2026-01-01 2026-09-30 0001837254 2025-01-01 2025-09-30 0001837254 us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-09-30 0001837254 us-gaap:CustomerConcentrationRiskMember us-gaap:OtherCustomerMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-09-30 0001837254 us-gaap:CustomerConcentrationRiskMember meha:Customer2Member us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-09-30 0001837254 us-gaap:CustomerConcentrationRiskMember meha:Customer1Member us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-09-30 0001837254 us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-09-30 0001837254 us-gaap:CustomerConcentrationRiskMember us-gaap:OtherCustomerMember us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-09-30 0001837254 us-gaap:CustomerConcentrationRiskMember meha:Customer2Member us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-09-30 0001837254 us-gaap:CustomerConcentrationRiskMember meha:Customer1Member us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-09-30 0001837254 meha:HempDerivedProductsMember 2025-01-01 2025-09-30 0001837254 meha:HempDerivedProductsMember 2026-01-01 2026-09-30 0001837254 meha:NutraceuticalsupplementsMember 2025-01-01 2025-09-30 0001837254 meha:NutraceuticalsupplementsMember 2026-01-01 2026-09-30 0001837254 us-gaap:CommonStockMember us-gaap:WarrantMember 2026-01-01 2026-09-30 0001837254 us-gaap:WarrantMember 2026-01-01 2026-09-30 0001837254 us-gaap:WarrantMember 2025-11-17 0001837254 us-gaap:WarrantMember 2025-11-05 0001837254 us-gaap:WarrantMember 2025-06-01 0001837254 us-gaap:WarrantMember 2025-03-10 0001837254 us-gaap:WarrantMember 2026-09-30 0001837254 us-gaap:WarrantMember 2025-01-01 2025-12-31 0001837254 us-gaap:WarrantMember 2025-12-31 0001837254 2026-05-11 2026-05-11 0001837254 meha:SeriesAAndSeriesBPreferredStockMember 2026-03-09 2026-03-09 0001837254 meha:FourHoldersMember 2026-09-30 0001837254 us-gaap:SeriesCPreferredStockMember 2026-01-01 2026-09-30 0001837254 us-gaap:SeriesCPreferredStockMember srt:MaximumMember 2026-01-01 2026-09-30 0001837254 us-gaap:SeriesCPreferredStockMember srt:MinimumMember 2026-01-01 2026-09-30 0001837254 us-gaap:SeriesCPreferredStockMember 2026-09-30 0001837254 us-gaap:CommonStockMember us-gaap:SeriesCPreferredStockMember us-gaap:CommonStockSubjectToMandatoryRedemptionMember 2026-01-01 2026-09-30 0001837254 us-gaap:SeriesCPreferredStockMember us-gaap:CommonStockSubjectToMandatoryRedemptionMember 2026-01-01 2026-09-30 0001837254 2025-12-31 0001837254 us-gaap:CommonStockMember 2026-09-30 0001837254 us-gaap:ConvertibleNotesPayableMember 2026-09-30 0001837254 us-gaap:SeriesCPreferredStockMember us-gaap:ConvertibleNotesPayableMember 2026-09-30 0001837254 us-gaap:ConvertibleNotesPayableMember 2026-05-11 0001837254 us-gaap:SeriesCPreferredStockMember 2026-05-11 0001837254 us-gaap:CommonStockMember 2026-03-09 0001837254 us-gaap:ConvertibleNotesPayableMember 2026-03-09 0001837254 meha:SeriesAAndSeriesBPreferredStockMember us-gaap:ConvertibleNotesPayableMember 2026-03-09 0001837254 us-gaap:CommonStockMember 2025-01-21 2025-01-21 0001837254 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-09-30 0001837254 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-09-30 0001837254 us-gaap:EmployeeStockOptionMember meha:TwoThousandTwentySixEquityIncentivePlanMember 2026-06-29 2026-06-29 0001837254 us-gaap:CommonStockMember meha:TwoThousandTwentySixEquityIncentivePlanMember 2026-05-01 2026-05-31 0001837254 us-gaap:CommonStockMember meha:TwoThousandTwentySixEquityIncentivePlanMember 2026-05-31 0001837254 meha:TwoZeroTwoSevenMember 2026-09-30 0001837254 us-gaap:ConvertibleDebtMember 2026-01-01 2026-09-30 0001837254 us-gaap:ConvertibleDebtMember 2026-07-01 2026-09-30 0001837254 2026-03-09 2026-09-30 0001837254 2026-03-08 0001837254 us-gaap:ConvertibleDebtMember 2026-03-09 2026-03-09 0001837254 meha:MeasurementInputProbabilityOfDilutiveFinancingMember us-gaap:FairValueInputsLevel3Member 2026-06-30 0001837254 meha:MeasurementInputProbabilityOfDilutiveFinancingMember meha:AtIssuanceMember us-gaap:FairValueInputsLevel3Member 2026-09-30 0001837254 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember us-gaap:FairValueInputsLevel3Member 2026-06-30 0001837254 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember us-gaap:FairValueInputsLevel3Member 2026-06-30 0001837254 us-gaap:MeasurementInputExpectedTermMember meha:AtIssuanceMember us-gaap:FairValueInputsLevel3Member 2026-09-30 0001837254 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:FairValueInputsLevel3Member 2026-06-30 0001837254 us-gaap:MeasurementInputExpectedDividendRateMember meha:AtIssuanceMember us-gaap:FairValueInputsLevel3Member 2026-09-30 0001837254 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:FairValueInputsLevel3Member 2026-06-30 0001837254 us-gaap:MeasurementInputRiskFreeInterestRateMember meha:AtIssuanceMember us-gaap:FairValueInputsLevel3Member 2026-09-30 0001837254 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:FairValueInputsLevel3Member 2026-06-30 0001837254 us-gaap:MeasurementInputPriceVolatilityMember meha:AtIssuanceMember us-gaap:FairValueInputsLevel3Member 2026-09-30 0001837254 us-gaap:MeasurementInputSharePriceMember us-gaap:FairValueInputsLevel3Member 2026-06-30 0001837254 us-gaap:MeasurementInputSharePriceMember meha:AtIssuanceMember us-gaap:FairValueInputsLevel3Member 2026-09-30 0001837254 meha:SeriesCPreferredStockAndConvertibleNoteMember 2026-09-30 0001837254 meha:SeriesCConvertibleNotesMember 2026-09-30 0001837254 meha:SeriesCPreferredStockAndConvertibleNoteMember 2026-07-01 2026-09-30 0001837254 meha:SeriesCConvertibleNotesMember 2026-07-01 2026-09-30 0001837254 us-gaap:SeriesCPreferredStockMember 2026-07-01 2026-09-30 0001837254 meha:SeriesCPreferredStockAndConvertibleNoteMember 2026-06-30 0001837254 meha:SeriesCConvertibleNotesMember 2026-06-30 0001837254 us-gaap:SeriesCPreferredStockMember 2026-06-30 0001837254 meha:MeasurementInputProbabilityOfDilutiveFinancingMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0001837254 meha:MeasurementInputProbabilityOfDilutiveFinancingMember meha:AtExchangeMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0001837254 us-gaap:MeasurementInputExpectedTermMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0001837254 us-gaap:MeasurementInputExpectedTermMember meha:AtExchangeMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0001837254 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0001837254 us-gaap:MeasurementInputExpectedDividendRateMember meha:AtExchangeMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0001837254 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0001837254 us-gaap:MeasurementInputRiskFreeInterestRateMember meha:AtExchangeMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0001837254 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0001837254 us-gaap:MeasurementInputPriceVolatilityMember meha:AtExchangeMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0001837254 us-gaap:MeasurementInputSharePriceMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0001837254 us-gaap:MeasurementInputSharePriceMember meha:AtExchangeMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0001837254 us-gaap:SeriesBPreferredStockMember 2025-12-31 0001837254 us-gaap:SeriesAPreferredStockMember 2025-12-31 0001837254 us-gaap:SeriesBPreferredStockMember 2026-01-01 2026-09-30 0001837254 us-gaap:SeriesAPreferredStockMember 2026-01-01 2026-09-30 0001837254 2025-01-01 2025-12-31 0001837254 us-gaap:SeriesAPreferredStockMember 2025-01-01 2025-12-31 0001837254 us-gaap:SeriesBPreferredStockMember 2025-01-01 2025-12-31 0001837254 us-gaap:SeriesBPreferredStockMember 2025-11-05 0001837254 us-gaap:SeriesAPreferredStockMember 2025-11-05 0001837254 us-gaap:LoansPayableMember 2025-12-31 0001837254 us-gaap:LoansPayableMember 2026-09-30 0001837254 us-gaap:LoansPayableMember 2025-01-01 2025-12-31 0001837254 us-gaap:LoansPayableMember 2026-01-01 2026-09-30 0001837254 us-gaap:LoansPayableMember 2024-12-31 0001837254 meha:LoanAgreementWithAThirdPartyMember 2026-01-01 2026-09-30 0001837254 meha:LoanAgreementWithAThirdPartyMember 2026-09-30 0001837254 meha:LoanAgreementWithAThirdPartyMember 2025-11-05 2025-11-05 0001837254 meha:LoanAgreementWithAThirdPartyMember 2025-11-05 0001837254 meha:LoanAgreementWithAThirdPartyMember 2025-08-29 2025-08-29 0001837254 meha:LoanAgreementWithAThirdPartyMember 2025-08-29 0001837254 meha:HemptownOrganicsCorpMember 2023-12-31 0001837254 us-gaap:RelatedPartyMember 2025-12-31 0001837254 us-gaap:RelatedPartyMember 2026-09-30 0001837254 us-gaap:RelatedPartyMember 2025-01-01 2025-12-31 0001837254 us-gaap:RelatedPartyMember 2026-01-01 2026-09-30 0001837254 us-gaap:RelatedPartyMember 2024-12-31 0001837254 meha:LoansPayableRelatedPartyMember 2025-03-10 0001837254 meha:LoansPayableRelatedPartyMember 2024-03-11 0001837254 meha:SBALoanPayableMember 2025-12-31 0001837254 meha:SBALoanPayableMember 2026-09-30 0001837254 meha:SBALoanPayableMember 2025-01-01 2025-12-31 0001837254 meha:SBALoanPayableMember 2026-01-01 2026-09-30 0001837254 meha:SBALoanPayableMember 2024-12-31 0001837254 meha:SmallBusinessAdministrationSBAMember 2020-07-07 0001837254 meha:ThirdPartyMember 2025-12-31 0001837254 meha:ThirdPartyMember 2025-01-01 2025-12-31 0001837254 meha:ThirdPartyMember 2026-01-01 2026-09-30 0001837254 meha:ThirdPartyMember 2024-12-31 0001837254 us-gaap:LineOfCreditMember 2025-08-19 0001837254 2025-08-01 2025-08-19 0001837254 srt:MinimumMember 2026-01-01 2026-09-30 0001837254 srt:MaximumMember 2026-01-01 2026-09-30 0001837254 meha:CustomerRelationshipMember 2025-12-31 0001837254 meha:CustomerRelationshipMember 2026-09-30 0001837254 meha:cGMPCertificationMember 2025-12-31 0001837254 meha:cGMPCertificationMember 2026-09-30 0001837254 meha:KirkmanBrandNetMember 2025-12-31 0001837254 meha:KirkmanBrandNetMember 2026-09-30 0001837254 2019-07-03 0001837254 2019-07-03 2019-07-03 0001837254 meha:Lease3EquipmentMember 2026-01-01 2026-09-30 0001837254 meha:Lease2EquipmentMember 2026-01-01 2026-09-30 0001837254 meha:LeasesTwoAndThreeEquipmentMember 2026-01-01 2026-09-30 0001837254 meha:LeasesTwoAndThreeEquipmentMember 2026-09-30 0001837254 meha:LeaseAgreementMember 2022-03-14 2022-03-14 0001837254 meha:LeaseAgreementMember 2021-09-30 2021-09-30 0001837254 meha:LeaseOneOperatingFacilityMember 2026-01-01 2026-09-30 0001837254 meha:LeaseOneOperatingFacilityMember 2023-01-01 2023-01-01 0001837254 meha:ProductionManufacturingAreaMember 2023-01-01 0001837254 us-gaap:BuildingMember 2023-01-01 0001837254 srt:MinimumMember 2023-01-01 0001837254 srt:MaximumMember 2023-01-01 0001837254 meha:OfficeEquipmentOneMember 2026-01-01 2026-09-30 0001837254 us-gaap:OfficeEquipmentMember 2026-01-01 2026-09-30 0001837254 meha:OperatingFacilityMember 2026-01-01 2026-09-30 0001837254 meha:OfficeEquipmentOneMember 2026-09-30 0001837254 us-gaap:OfficeEquipmentMember 2026-09-30 0001837254 meha:OperatingFacilityMember 2026-09-30 0001837254 2024-12-31 0001837254 2025-07-01 2025-09-30 0001837254 meha:Customer1Member us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2026-01-01 2026-09-30 0001837254 us-gaap:WarrantMember 2025-01-01 2025-09-30 0001837254 us-gaap:SeriesCPreferredStockMember us-gaap:CommonStockMember 2026-01-01 2026-09-30 0001837254 us-gaap:SeriesBPreferredStockMember us-gaap:CommonStockMember 2026-01-01 2026-09-30 0001837254 meha:KirkmanBrandMember 2026-01-01 2026-09-30 0001837254 meha:GoodwillincludingAssembledWorkforceMember 2026-01-01 2026-09-30 0001837254 meha:cGMPCertificationMember 2026-01-01 2026-09-30 0001837254 us-gaap:CustomerRelationshipsMember 2026-01-01 2026-09-30 0001837254 us-gaap:ComputerEquipmentMember 2026-01-01 2026-09-30 0001837254 us-gaap:FurnitureAndFixturesMember 2026-01-01 2026-09-30 0001837254 us-gaap:MachineryAndEquipmentMember 2026-01-01 2026-09-30 0001837254 us-gaap:DepositsMember 2025-12-31 0001837254 us-gaap:DepositsMember 2026-09-30 0001837254 meha:HTOHoldingsInc.Member 2023-05-19 2023-05-19 0001837254 us-gaap:PreferredStockMember 2025-01-22 0001837254 us-gaap:CommonStockMember 2025-01-22 2025-01-22 0001837254 2025-09-30 0001837254 us-gaap:RetainedEarningsMember 2026-09-30 0001837254 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001837254 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2026-09-30 0001837254 us-gaap:RetainedEarningsMember 2026-01-01 2026-09-30 0001837254 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-09-30 0001837254 us-gaap:CommonStockMember 2026-01-01 2026-09-30 0001837254 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2026-01-01 2026-09-30 0001837254 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-01-01 2026-09-30 0001837254 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-01-01 2026-09-30 0001837254 us-gaap:RetainedEarningsMember 2025-12-31 0001837254 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001837254 us-gaap:CommonStockMember 2025-12-31 0001837254 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0001837254 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0001837254 us-gaap:RetainedEarningsMember 2025-09-30 0001837254 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001837254 us-gaap:CommonStockMember 2025-09-30 0001837254 us-gaap:RetainedEarningsMember 2025-01-01 2025-09-30 0001837254 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-09-30 0001837254 us-gaap:CommonStockMember 2025-01-01 2025-09-30 0001837254 us-gaap:RetainedEarningsMember 2024-12-31 0001837254 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001837254 us-gaap:CommonStockMember 2024-12-31 0001837254 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001837254 2026-06-30 0001837254 us-gaap:RetainedEarningsMember 2026-06-30 0001837254 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001837254 us-gaap:CommonStockMember 2026-06-30 0001837254 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2026-06-30 0001837254 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001837254 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001837254 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001837254 2025-06-30 0001837254 us-gaap:RetainedEarningsMember 2025-06-30 0001837254 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001837254 us-gaap:CommonStockMember 2025-06-30 0001837254 us-gaap:SeriesCPreferredStockMember 2025-12-31 0001837254 us-gaap:SeriesBPreferredStockMember 2026-09-30 0001837254 us-gaap:SeriesAPreferredStockMember 2026-09-30 0001837254 2026-11-13 0001837254 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001837254 meha:CommonStockToBeIssuedMember 2026-07-01 2026-09-30 0001837254 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001837254 meha:CommonStockToBeIssuedMember 2026-01-01 2026-09-30 0001837254 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-07-01 2025-09-30 0001837254 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-07-01 2025-09-30 0001837254 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2025-07-01 2025-09-30 0001837254 meha:CommonStockToBeIssuedMember 2025-07-01 2025-09-30 0001837254 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-07-01 2026-09-30 0001837254 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-07-01 2026-09-30 0001837254 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2026-07-01 2026-09-30 0001837254 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-01-01 2025-09-30 0001837254 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-01-01 2025-09-30 0001837254 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2025-01-01 2025-09-30 0001837254 meha:CommonStockToBeIssuedMember 2025-01-01 2025-09-30 0001837254 meha:ThirdPartyMember 2026-09-30 0001837254 meha:CommonStockToBeIssuedMember 2025-09-30 0001837254 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-09-30 0001837254 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-09-30 0001837254 meha:CommonStockToBeIssuedMember 2026-09-30 0001837254 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001837254 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001837254 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001837254 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0001837254 meha:CommonStockToBeIssuedMember 2025-12-31 0001837254 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-06-30 0001837254 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-06-30 0001837254 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2025-06-30 0001837254 meha:CommonStockToBeIssuedMember 2025-06-30 0001837254 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-06-30 0001837254 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-06-30 0001837254 meha:CommonStockToBeIssuedMember 2026-06-30 0001837254 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-09-30 0001837254 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-09-30 0001837254 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2025-09-30 0001837254 us-gaap:SeriesAPreferredStockMember 2024-12-31 0001837254 us-gaap:SeriesBPreferredStockMember 2024-12-31 0001837254 us-gaap:SeriesCPreferredStockMember 2024-12-31 0001837254 meha:SeriesCConvertibleNotesMember 2024-12-31 0001837254 meha:SeriesCPreferredStockAndConvertibleNoteMember 2024-12-31 0001837254 us-gaap:SeriesCPreferredStockMember 2025-01-01 2025-12-31 0001837254 meha:SeriesCConvertibleNotesMember 2025-01-01 2025-12-31 0001837254 meha:SeriesCPreferredStockAndConvertibleNoteMember 2025-01-01 2025-12-31 0001837254 meha:TwoZeroTwoSixMember 2026-09-30 0001837254 meha:KirkmanMember 2026-01-01 2026-09-30 0001837254 meha:SeriesCConvertibleNotesMember 2025-12-31 0001837254 meha:SeriesCPreferredStockAndConvertibleNoteMember 2025-12-31 iso4217:USD xbrli:shares xbrli:pure meha:Segments iso4217:USD xbrli:shares utr:sqft

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2026

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File Number: 001-42936

 

FUNCTIONAL BRANDS INC.

(Exact name of registrant as specified in its charter)

 

Delaware   85-4094332
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification Number)
     
6400 SW Rosewood Street, Lake Oswego, Oregon   97035
(Address of principal executive offices)   (Zip Code)

 

(800) 245-8282
(Registrant’s telephone number, including area code)
 
NONE
(Former name or former address, if changed since last report.)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of Each Exchange On Which Registered
Common Stock, $0.00001 par value share   MEHA   OTC Markets

 

Indicate by checkmark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer ☐ Accelerated Filer ☐ Non-Accelerated Filer ☒ Smaller Reporting Company ☒
      Emerging Growth Company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with a new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by checkmark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

The number of shares of registrant’s common stock outstanding as of November 13, 2026: 64,921,095.

 

 

 

 

 

 

FUNCTIONAL BRANDS INC.

 

TABLE OF CONTENTS

 

      Page No.
PART I.   FINANCIAL INFORMATION 1
  Item 1. Consolidate Financial Statements (Unaudited) 1
    Unaudited Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025 1
    Unaudited Consolidated Statements of Operations for the three and nine months ended September 30, 2026 and 2025 2
    Unaudited Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the three and nine months ended September 30, 2026 and 2025 3
    Unaudited Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 and 2025 5
    Notes to Unaudited Consolidated Financial Statements 6
  Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 27
  Item 3. Quantitative and Qualitative Disclosures about Market Risk 37
  Item 4. Controls and Procedures 37
PART II.   OTHER INFORMATION 38
  Item 1. Legal Proceedings 38
  Item 1A. Risk Factors 38
  Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 39
  Item 3. Defaults Upon Senior Securities 39
  Item 4. Mine Safety Disclosures 39
  Item 5. Other Information 39
  Item 6. Exhibits 40
PART III.   Signatures 41

 

i

 

 

PART I. FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

FUNCTIONAL BRANDS INC.

CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(In U.S. dollars, except share data or otherwise noted)

 

    September 30,     December 31,  
    2026     2025  
Assets            
Current assets:            
Cash   $ 231,900     $ 2,726,696  
Accounts receivable, net     298,965       518,474  
Inventories, net     1,713,600       1,549,511  
Prepaid expenses and other current assets     267,981       392,999  
Total current assets     2,512,446       5,187,680  
Noncurrent assets:                
Property and equipment, net     23,890       37,379  
Right-of-use assets, net     1,397,823       1,667,693  
Intangible assets, net     1,362,814       1,397,411  
Goodwill     818,139       818,139  
Total non-current assets     3,602,666       3,920,622  
Total assets   $ 6,115,112     $ 9,108,302  
Liabilities and stockholders’ equity / (deficit)                
Current liabilities:                
Accounts payable and accrued liabilities   $ 2,556,599     $ 1,554,243  
Line of credit     -       8,109  
SBA loan, current     3,668       3,595  
Lease liabilities, current     384,181       371,272  
Other current liabilities     45,271       41,828  
Loans payable (related party), current     70,709       61,642  
Loans payable     162,310       402,650  
Convertible note     993,525       -  
Derivative liabilities     1,336,740       3,306,745  
Preferred shares liabilities     2,764,000       -  
Total current liabilities     8,317,003       5,750,084  
Non-current liabilities:                
Lease liabilities, net of current     1,143,405       1,435,505  
SBA loan, net of current     134,112       136,873  
Loan payable (related party), net of current     190,284       244,509  
Total non-current liabilities     1,467,801       1,816,887  
Total liabilities     9,784,804       7,566,971  
Stockholders’ equity / (deficit)                
Series A Preferred stock, par value $0.001 stated value $100, 100,000 shares authorized in 2026 and 2025; 0 and 87,445 shares issued and outstanding, respectively     -       87  
Series B Preferred stock, par value $0.001 stated value $100, 80,000 shares authorized in 2026 and 2025; 0 and 28,475 shares issued and outstanding, respectively     -       28  
Series C Preferred stock, par value $0.001 stated value $1,000, 6,100 and 0 authorized in 2026 and 2025; 2,764 and 0 shares issued and outstanding, respectively     -       -  
Common stock, $0.00001 par value, 220,000,000 shares authorized, 64,921,095 and 18,704,649 shares outstanding     650       187  
Additional paid-in capital     13,723,825       8,522,354  
Accumulated deficit     (17,394,167 )     (6,981,325 )
Total stockholders’ equity / (deficit)     (3,669,692 )     1,541,331  
Total liabilities and stockholders’ equity / (deficit)   $ 6,115,112     $ 9,108,302  

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

1

 

 

FUNCTIONAL BRANDS INC.

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(In U.S. dollars, except share data or otherwise noted)

 

    Three Months Ended     Nine Months Ended  
    September 30,     September 30,     September 30,     September 30,  
    2026     2025     2026     2025  
Revenue, net of returns     1,645,053       1,694,174       5,161,125       5,116,963  
Cost of goods sold     684,289       715,824       2,118,887       2,303,752  
Gross profit     960,764       978,350       3,042,238       2,813,211  
Operating expenses                                
Sales and marketing     198,630       118,876       802,721       462,545  
General and administrative     1,076,896       937,762       4,557,482       2,616,489  
Total operating expenses     1,275,526       1,056,638       5,360,203       3,079,034  
Operating loss     (314,762 )     (78,288 )     (2,317,965 )     (265,823 )
Other income / (expense)                                
Interest income     1,266       72,652       8,413       73,344  
Other income     -       -       61       112  
Other income – ERTC refund     -       419,947       -       419,947  
Interest expense     (246,165 )     (155,310 )     (369,770 )     (321,417 )
Other expenses     -               (50,000 )        
Change in fair value of derivative liabilities     (154,794 )     -       (1,097,362 )     -  
Loss on issuance of preferred stock     -       -       (6,310,464 )     -  
Loss on default     -       -       (198,705 )     -  
Total other income / (expense)     (399,693 )     337,289       (8,017,827 )     171,986  
Net loss   $ (714,455 )   $ 259,001     $ (10,335,792 )   $ (93,837 )
Net loss per share of common stock attributable to common stockholders                                
Basic   $ (0.01 )   $ 0.04     $ (0.24 )   $ (0.01 )
Diluted   $ (0.01 )   $ 0.04     $ (0.24 )   $ (0.01 )
Weighted average shares used in computing net loss per share of common stock                                
Basic     64,921,095       7,039,144       42,639,875       6,953,265  
Diluted     64,921,095       7,197,605       42,639,875       6,953,265  

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

2

 

 

FUNCTIONAL BRANDS INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY / (DEFICIT) (UNAUDITED)

(In U.S. dollars, except share data or otherwise noted)

 

For the Three Months Ended September 30, 2025

 

    Preferred Stock                 Common Stock                 Total  
    Series A     Series B     Series C     Common Stock     to be issued           Accumulated     Stockholders’  
    Shares     Amount     Shares     Amount     Shares     Amount     Shares     Amount     Shares     Amount     APIC     Deficit     Equity  
Balance as of June 30, 2025            -     $        -              -     $        -              -     $        -       7,027,269     $ 70              -     $        -     $ 8,270,862     $ (8,013,768 )   $ 257,164  
Stock based compensation     -       -       -       -       -       -       -       -       -       -       8,000       -       8,000  
Shares issued for financing     -       -       -       -       -       -       57,500       1       -       -       80,499       -       80,500  
Net income     -       -       -       -       -       -       -       -       -       -       -       259,001       259,001  
Balance as of September 30, 2025     -     $ -       -     $ -       -     $ -       7,084,769     $ 71       -     $ -     $ 8,359,361     $ (7,754,767 )   $ 604,665  

 

For the Three Months Ended September 30, 2026

 

    Preferred Stock                 Common Stock                 Total  
    Series A     Series B     Series C     Common Stock     to be issued           Accumulated     Stockholders’  
    Shares     Amount     Shares     Amount     Shares     Amount     Shares     Amount     Shares     Amount     APIC     Deficit     Equity /  (Deficit)  
Balance as of June 30, 2026            -     $        -              -     $        -       2,764     $        -       64,921,095     $ 650              -     $        -     $ 13,723,825     $ (16,679,712 )   $ (2,955,237 )
Conversion of preferred stock     -       -       -       -       -       -       -       -       -       -       -       -       -  
Buyback of preferred stock     -       -       -       -       -       -       -       -       -       -       -       -       -  
Stock based compensation     -       -       -       -       -       -       -       -       -       -       -       -       -  
Shares issued as part of exchange agreement     -       -       -       -       -       -       -       -       -       -       -       -       -  
Warrant exercises     -       -       -       -       -       -       -       -       -       -       -       -       -  
Preferred stock dividends     -       -       -       -       -       -       -       -       -       -       -       -       -  
Conversion of convertible notes     -       -       -       -       -       -       -       -       -       -       -       -       -  
Net loss     -       -       -       -       -       -       -       -       -       -       -       (714,455 )     (714,455 )
Balance as of September 30, 2026     -     $ -       -     $ -       2,764     $ -       64,921,095     $ 650       -     $ -     $ 13,723,825     $ (17,394,167 )   $ (3,669,692 )

 

3

 

 

For the Nine Months Ended September 30, 2025

 

    Preferred Stock                 Common Stock                 Total  
    Series A     Series B     Series C     Common Stock     to be issued           Accumulated     Stockholders’  
    Shares     Amount     Shares     Amount     Shares     Amount     Shares     Amount     Shares     Amount     APIC     Deficit     Equity  
Balance as of December 31, 2024            -     $        -              -     $        -                   $        -       6,694,880     $ 67                                 $ 7,542,286     $ (7,660,930 )   $ (118,577 )
Stock based compensation     -       -       -       -       -       -       180,866       1       -       -       518,354       -       518,355  
Common stock issued for convertible notes payable and accrued interest     -       -       -       -       -       -       133,441       1       -       -       122,330       -       122,331  
Warrants issued with respect of loan payable     -       -       -       -       -       -       -       -       -       -       45,263       -       45,263  
Issuance of shares to debenture holder     -       -       -       -       -       -       18,082       1       -       -       50,629       -       50,630  
Shares issued for note extension     -       -       -       -       -       -       57,500       1       -       -       80,499       -       80,500  
Net income     -       -       -       -       -       -       -       -       -       -       -       (93,837 )     (93,837 )
Balance as of September 30, 2025     -     $ -       -     $  -       -     $ -       7,084,769     $ 71       -       -     $ 8,359,361     $ (7,754,767 )   $ 604,665  

 

For the Nine Months Ended September 30, 2026

 

    Preferred Stock                 Common Stock                 Total  
    Series A     Series B     Series C     Common Stock     to be issued           Accumulated     Stockholders’  
    Shares     Amount     Shares     Amount     Shares     Amount     Shares     Amount     Shares     Amount     APIC     Deficit     Equity /  (Deficit)  
Balance as of December 31, 2025     87,445     $ 87       28,475     $ 28             -     $       -       18,704,649     $ 187     $       -     $       -     $ 8,522,354     $ (6,981,325 )   $ 1,541,331  
Conversion of preferred stock     -       -       (6,402 )     (6 )     (3,268 )     -       28,390,770       284       -       -       3,365,424       -       3,365,702  
Buyback of preferred stock     (12,445 )     (12 )     -       -       -       -       -       -       -       -       (150,583 )     -       (150,595 )
Stock based compensation     -       -       -       -       -       -       -       -       -       -       437,973       -       437,973  
Shares issued as part of exchange agreement     (75,000 )     (75 )     (22,073 )     (22 )     6,032               5,190,171       52       -       -       1,037,982       -       1,037,937  
Warrant exercises     -       -       -       -       -       -       5,480,645       55       -       -       (53 )     -       2  
Preferred stock dividends     -       -       -       -       -       -       -       -       -       -       -       (77,050 )     (77,050 )
Conversion of convertible notes     -       -       -       -       -       -       7,154,860       72       -       -       510,728       -       510,800  
Net loss     -       -       -       -       -       -       -       -       -       -       -       (10,335,792 )     (10,335,792 )
Balance as of September 30, 2026     -     $ -       -     $ -       2,764     $ -       64,921,095     $ 650       -     $ -     $ 13,723,825     $ (17,394,167 )   $ (3,669,692 )

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

4

 

 

FUNCTIONAL BRANDS INC.

CONSOLIDATED STATEMENTS OF CASH FLOW (UNAUDITED)

(In U.S. dollars, except share data or otherwise noted)

 

    Nine Months Ended  
    September 30,     September 30,  
    2026     2025  
Cash flows from operating activities:            
Net loss   $ (10,335,792 )   $ (93,837 )
Reconcile net loss to cash provided by operating activities                
Allowance for doubtful accounts receivable     -       (3,796 )
Allowance for inventory obsolescence     (2,075 )     12,895  
Depreciation of property and equipment     13,489       15,990  
Amortization of right-of-use assets     269,870       246,511  
Amortization of intangible assets     34,597       34,597  
Stock-based compensation     437,973       598,856  
Issuance of shares to debenture holder     -       50,630  
Issuance of warrants     -       45,263  
Change in fair value of derivative liabilities     1,097,362       -  
Loss on issuance of convertible note     198,705       -  
Loss on issuance of preferred stock     6,310,464       -  
Dividends     (77,050 )     -  
Changes in operating assets and liabilities:                
Accounts receivable     219,509       218,054  
Inventories     (162,014 )     5,830  
Prepaid expenses and other current assets     125,018       1,042  
Accounts payable and accrued liabilities     1,127,480       591,172  
Other current liabilities     3,443       (908 )
Lease liabilities     (279,191 )     (243,941 )
Net cash (used in) provided by operating activities     (1,018,212 )     1,478,358  
Cash flows from investing activities:                
Purchase of property and equipment     -       (8,512 )
Net cash provided by (used in) investing activities     -       (8,512 )
Cash flows from financing activities:                
Deferred offering costs     -       (667,810 )
Dividends paid     (114,262 )     -  
Proceeds from loans     32,707       195,277  
Payments for payable for acquisition     -       (115,000 )
Repayment of liability conditional timing     (450,000 )     -  
Repayment of loans     (318,205 )     (75,106 )
Buyback of preferred stock     (616,027 )     -  
Proceeds from line of credit     -       99,735  
Line of credit repayment     (8,109 )     (110,683 )
SBA loan repayment     (2,688 )     (2,577 )
Net cash used in financing activities     (1,476,584 )     (676,164 )
Increase (decrease) in cash     (2,494,796 )     793,682  
Cash beginning of period     2,726,696       211,642  
Cash, end of period   $ 231,900     $ 1,005,324  
Supplemental disclosures of cash flow information                
Cash paid for interest   $ 56,220     $ 241,662  
Non-cash investing and financing activities                
Common stock issued for convertible note payable and accrued interest     -     $ 122,331  
Loan payable, related party     -     $ 225,000  
Derecognition of derivative liabilities upon extinguishment of Series A&B preferred shares   $ (97 )   $ -  
Extinguishment of Series A&B preferred shares   $ (3,027,287 )   $ -  
Issuance of Series C preferred shares   $ (6,032,160 )   $ -  
Recognition of derivative liabilities upon issuance of Series C preferred shares & convertible notes   $ (529,854 )   $ -  
Recognition of Series C convertible notes   $ (837,000 )   $ -  
Warrant exercise   $ 2     $ -  

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

5

 

 

FUNCTIONAL BRANDS INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

1. Organization and Nature of Operations

 

Functional Brands Inc. (formerly HT Naturals Inc., the “Company”) was organized under the General Corporation Law in the State of Delaware on November 19, 2020. The Company’s principal business is the production, marketing, sales, and distribution of nutraceutical products within the U.S. and in 21 other countries globally.

 

On March 22, 2023, the Company changed its name from HT Naturals Inc. to Functional Brands Inc. to better reflect its corporate identity.

 

On January 22, 2025, the Company effected a 1-for-18.338622 reverse stock split of its outstanding common stock. The authorized common stock of the Company remained unchanged at 220,000,000. All references to share and per share amounts in the consolidated financial statements and accompanying notes thereto have been retroactively restated to reflect the reverse stock split. In addition, the Company authorized 1,000,000 shares of blank check preferred $0.001 par value.

 

As of September 30, 2026, and 2025, the consolidated financial statements consist of the Company and its wholly owned subsidiary HTO Nevada Inc. (d/b/a Kirkman), which is a nutraceutical manufacturer and distributor based in the Pacific Northwest. All intercompany transactions and balances have been eliminated in consolidation.

 

2. Summary of Significant Accounting Policies

 

Going Concern

 

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. For the nine months ended September 30, 2026, the Company had net loss of $10,335,792, and a working capital deficit of $5,804,557, and an accumulated deficit of $17,394,167. As of September 30, 2026 the Company had cash of $231,900.

 

In addition, the Company is in default under its Series C Convertible Preferred Shares and its Senior Secured Convertible Notes as a result of its failure to commence the Series C mandatory redemption (effective June 8, 2026) and the delisting of its common stock from the Nasdaq Capital Market (effective June 16, 2026). As a result, the holders have the right to accelerate the Notes, the Notes have been classified as current liabilities, default-rate interest and a default premium apply, and the outstanding Series C stated value of $2,764,000 is subject to mandatory redemption. These obligations exceed the Company’s available cash and expected cash from operations, and the Company does not have committed financing sufficient to satisfy them. As of the date of this report, no holder has accelerated the Notes or the Series C. See Notes 16 and 19.

 

These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management is in discussions with the holders and is evaluating alternatives, which may include waivers, forbearance, amendments, restructuring or refinancing of the instruments, and additional equity or debt financing. Because none of these plans had been finalized or approved as of the date these consolidated financial statements were issued, and their implementation depends on parties outside the Company’s control, management has concluded that it is not probable that the plans will be effectively implemented or will mitigate the relevant conditions. Accordingly, management has concluded that substantial doubt about the Company’s ability to continue as a going concern within one year after the date these consolidated financial statements are issued has not been alleviated. There can be no assurance that any of these alternatives will be available on acceptable terms, or at all.

 

In order to continue as a going concern, the Company will need, among other things, additional capital resources. The Company is significantly dependent upon its ability to secure additional equity and/or debt financing. There are no assurances that the Company will be successful in obtaining additional capital.

 

The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

6

 

 

Unaudited Financial Information

 

The Company’s unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial reporting and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Pursuant to these rules and regulations, they do not include all information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, the unaudited consolidated financial statements reflect all adjustments, consisting of a normal recurring nature, considered necessary for a fair statement of the Company’s financial condition and results of operations. Operating results for the periods presented are not necessarily indicative of the results that might be expected for the full year. As such, the information included in this report should be read in conjunction with the Company’s audited consolidated financial statements as of and for the year ended December 31, 2025, which are included in the Company’s Form 10-K, dated and filed with the SEC on March 27, 2026, which is accessible on the SEC’s website at www.sec.gov.

 

During the nine months ended September 30, 2026, there were no changes to the Company’s significant accounting policies as described in the Company’s audited consolidated financial statements as of and for the year ended December 31, 2025.

 

Principles of Consolidation

 

The financial statements of the subsidiary are prepared for the same reporting period as the parent company, using consistent accounting policies.

 

Functional Brands Inc. (formerly HT Naturals Inc.)

 

● Functional Brands Inc. (formerly HT Naturals Inc.) is the parent company.

 

HTO Nevada Inc. dba Kirkman

 

● HTO Nevada Inc. dba Kirkman, which is owned by the Company is the sole subsidiary.

 

As part of the restructuring efforts, ownership of HTO Nevada Inc. dba Kirkman was transferred from HTO Holdings Inc. to Functional Brands Inc. (formerly HT Naturals Inc.) on May 19, 2023, in exchange for 4,362,378 shares of common stock of the Company. This was retroactively recorded in 2019 as the acquisition was completed on July 3, 2019, with entities under common control.

 

Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications had no effect on previously reported net income or stockholders’ equity.

 

Use of Estimates

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates and be based on events different from those assumptions. Future events and their effects cannot be predicted with certainty; estimating, therefore, requires the exercise of judgment. Thus, accounting estimates change as new events occur, as more experience is acquired, or as additional information is obtained.

 

Cash

 

Cash consists of cash in readily available checking accounts and deposits in transit. As of September 30, 2026 and December 31, 2025, cash balances were deposited at major and other financial institutions. On September 30, 2026 and December 31, 2025, the Company had $40,196 and $2,085,978, respectively, of cash in excess of FDIC limits of $250,000. Any loss incurred or a lack of access to such funds above the FDIC limit could have a significant adverse impact on the Company’s financial condition, results of operations and cash flows.

 

7

 

 

Accounts Receivable, net

 

Accounts receivable consists of trade receivables arising from contracts with customers, are recorded at the invoiced amount, and do not bear interest. The Company maintains an allowance for credit losses in accordance with ASC 326, Financial Instruments – Credit Losses, representing management’s estimate of expected credit losses over the contractual life of the receivables. Receivables with similar risk characteristics are evaluated on a pooled basis using historical collection experience, the aging of balances, and the financial condition of customers, adjusted for current conditions and reasonable and supportable forecasts. Receivables that do not share similar risk characteristics are evaluated individually. Balances are written off against the allowance when collection efforts have been exhausted and recovery is considered remote.

 

Inventories

 

Inventory consists of raw materials, packaging supplies and finished goods. Inventory is measured at the lower of cost or net realizable value. Inventory costs include direct labor and certain overhead expenses such as in-bound shipping and handling costs incurred to bring the inventory to its present location and conditions. Cost is determined by using the weighted average method. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses. If the Company determines that the estimated net realizable value of its inventory is less than the carrying value of such inventory, it records a charge to impairment expenses.

 

As of September 30, 2026 and December 31, 2025 there was no impairment to the Company’s net realizable value of its inventory.

 

Property and Equipment

 

Property and equipment are stated at cost. Depreciation of property and equipment is recorded using the straight-line method over the assets’ estimated useful lives. Amortization of fixed assets under capital leases is included in depreciation expense.

 

The categories of capital assets are amortized on a straight-line basis as follows:

 

  ● Machinery and equipment 7 years, straight-line

 

  ● Furniture and fixtures 7 years, straight-line

 

  ● Computer equipment 5 years, straight-line

 

The Company allocates the amount initially recognized for a capital asset to its significant parts and amortizes separately each part. Residual values, methods of amortization and useful lives of the capital assets are reviewed annually and adjusted if appropriate.

 

The assets’ residual values, useful lives and methods of depreciation are reviewed at each fiscal year-end and adjusted prospectively if appropriate. An item of equipment is retired upon disposal or when no future economic benefits are expected from its use. Any gain or loss arising on sale or retirement of the asset (calculated as the difference between the net disposal proceeds and the carrying value of the asset) is included in the consolidated statement of operations in the year the asset is retired. Such assets are tested annually for impairment, or more frequently, if events or changes in circumstances indicate that they might be impaired.

 

8

 

 

Intangible Assets

 

Intangible assets are recorded at cost, less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. Amortization is provided on a straight-line basis over their estimated useful lives, which do not exceed the contractual period, if any. Intangible assets that have indefinite useful lives are not subject to amortization and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. The estimated useful lives, residual values, and amortization methods are reviewed at each year end, and any changes in estimates are accounted for prospectively.

 

The categories of the intangible assets are amortized on a straight-line basis as follows:

 

  ● Customer relationships 10 years

 

  ● cGMP certification Indefinite life

 

  ● Goodwill (including Assembled Workforce) Indefinite life

 

  ● Kirkman brand Indefinite life

 

Expenditures in the research phase and post-development maintenance costs are expensed as incurred.

 

Goodwill

 

Goodwill arises from business combinations and is generally determined as the excess of the fair value of the consideration transferred, plus the fair value of any non-controlling interests in the acquire, over the fair value of the net assets acquired and liabilities assumed as of the acquisition date. Goodwill acquired in a business combination is not amortized but tested for impairment at least annually or more frequently if events and circumstances exist that indicate that a goodwill impairment test should be performed.

 

Goodwill is tested for impairment at the reporting unit level. A reporting unit is an operating segment or one level below an operating segment (referred to as a component). The Company allocates goodwill to reporting units based on the reporting unit expected to benefit from the business combination. Assets and liabilities are assigned to each reporting unit if they are employed by a reporting unit and are considered in the determination of the reporting unit fair value. The Company has one reporting unit with goodwill, which is the Kirkman business.

 

The Company’s indefinite-lived intangible assets are tested for impairment at the consolidated level. In evaluating the recoverability of the Kirkman brand name and Current Good Manufacturing Practice (“cGMP”) certification which refers to U.S. Food and Drug Administration (“FDA”) regulations ensuring that food, drug, and medical device manufacturers maintain high standards for safety, quality, and purity through proper design, monitoring, and control of manufacturing processes and facilities. The Company compared the fair value of the asset to its carrying amount to determine potential impairment. The Company’s estimate of the fair value of the Kirkman brand name is derived using the income approach, specifically the relief-from-royalty method and the fair value of the cGMP certification is derived using the income approach.

 

The fair value determination of the reporting units and the indefinite-lived intangible asset is judgmental in nature and requires the use of significant estimates and assumptions that are sensitive to changes. Assumptions include estimation of the royalty rate, estimation of future revenue and projected margins, which are dependent on internal cash flow forecasts, estimation of the terminal growth rates and capital spending, and determination of discount rates. As a result, there can be no assurance that the estimates and assumptions made for purposes of quantitative goodwill and indefinite-lived intangible impairment tests will prove to be an accurate prediction of future results. Examples of events or circumstances that could reasonably be expected to negatively affect the underlying key assumptions and ultimately impact the estimated fair value of the reporting units may include such items as: (i) volatility in the equity and debt markets or other macroeconomic factors, (ii) an increase in the weighted-average cost of capital due to further increases in interest rates, (iii) decrease in future cash flows due to lower than expected sales, or (iv) fluctuations in foreign currency exchange rates that may negatively impact the Company’s reported results of operations. Accordingly, if the current cash flow assumptions are not realized, we experience further increases in costs of capital, it is possible that an additional impairment charge may be recorded in the future, which could be material.

 

9

 

 

Right-of-Use Assets and Lease Liabilities

 

The Company accounts for leases in accordance with ASC 842, Leases. At the commencement date of a lease, the Company recognizes a right-of-use (“ROU”) asset and a corresponding lease liability, measured at the present value of the lease payments over the lease term. The Company discounts lease payments using the rate implicit in the lease, if readily determinable, and otherwise its incremental borrowing rate. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has made an accounting policy election not to recognize lease assets or liabilities for leases with a term of 12 months or less. Assets under finance leases are included in property and equipment and depreciated over the useful life of the underlying asset, as the Company expects to exercise the related purchase options.

 

Derivative Liabilities

 

The Company’s accounting for the Series A, Series B and Series C Convertible Preferred Stock, the Senior Secured Convertible Promissory Notes and the related embedded derivative liabilities is described in Notes 15, 16 and 18.

 

Stock-Based Compensation Plan

 

The Board of Directors has authorized with shareholder’s approved the 2026 Equity Incentive Plan that may be used to compensate or reward the members of its board of directors, executive officers, employees and consultants for services rendered.

 

No expense is recognized for performance-based awards that do not vest. Expense for service-based award is recognized upon receipt of the agreed upon services. Where the terms of an equity settled award are modified, the minimum expense recognized is the expense as if the terms had not been modified. An additional expense is recognized for any modification which increases the total fair value of the share-based payment arrangement or is otherwise beneficial to the employee as measured at the date of modification.

 

Compensation expense is recognized for all share-based payments to employees and non-employees, including restricted stock units and options “instruments” in the statements of operation based on the fair value of the awards that are granted. As necessary, the Company’s stock price at the date of grant was estimated using an acceptable valuation technique such as a recent round of fundraising or the probability-weighted expected return model. The fair value of instruments granted before the Nasdaq public listing was assessed at the grant date, using the share price established in the most recent 409a valuation report conducted by an external appraiser. For future RSU grants, fair value will be based on the Company’s stock price at the time of issuance.

 

Compensation expense for restricted stock awards with performance-based vesting conditions is calculated based on the number of awards that are expected to vest during the performance period if it is probable that the performance metrics will be achieved. Generally, measured compensation cost, net of actual forfeitures, is recognized on a straight-line basis over the vesting period of the related share-based compensation award. The Company accounts for forfeitures of stock-based awards as they occur.

 

Revenue Recognition

 

The Company accounts for revenue in accordance with ASC Topic 606, “Revenue from Contracts with Customers”. Revenue is measured based on the amount of consideration that we expect to receive, reduced by discounts and estimates for credits and returns (calculated based upon previous experience and management’s evaluation). Outbound shipping charged to customers is recognized at the time the related merchandise revenues are recognized and are included in net revenues.

 

Per Company policy, any product that does not meet the customer’s expectations can be returned within 30 days of delivery in exchange for another product, or for a full refund. Any product sold through a distributor or retailer must be returned to the original purchase location for any return or exchange. For the nine months ended September 30, 2026 and 2025, the Company did not record any reserves on revenue for product returns or exchanges.

 

10

 

 

Earnings / (Loss) per Share

 

Basic earnings / (loss) per common share is calculated by dividing the net income (loss) distributed to the common class minus the preferred stock dividends, by the weighted-average number of shares outstanding during the period, without consideration for potentially dilutive securities. Diluted earnings (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted-average number of shares and potentially dilutive securities outstanding for the period.

 

For purposes of the diluted net loss per share calculation, restricted stock units (RSUs), outstanding warrants, conversion of Series B and Series C Preferred stock, and conversion of convertible notes. are considered to be potentially dilutive securities.

 

As of September 30, 2026, 22,972,245 shares of common stock to be issued upon conversion of Series C Preferred shares, 7,154,860 shares of common stock to be issued upon conversion of Convertible notes,5,480,645 shares of commons stock upon conversion of warrants, and 750,000 shares to be issued in lieu of services, all are potentially common stock equivalents and are excluded from the diluted loss per share calculations as their effect is anti-dilutive. As a result, diluted net loss per share for the three and nine months ended September 30, 2026, is the same as basic net loss per share.

 

As of September 30, 2025, there were 83,501 RSUs and 37,500 warrants of potentially common stock equivalents excluded from the diluted loss per share calculations as their effect is anti-dilutive. As a result, diluted net loss per share for the nine months ended September 30, 2025 is the same as basic net loss per share. For the three months ending September 30, 2025, the stock equivalents were included in the dilutive as the company had net income.

 

The following is a reconciliation of the numerator and denominator used in the basic and diluted earnings (loss) per share (“EPS”) calculations for the three and nine months ended September 30, 2026 and 2025.

 

    9 Months Ending     3 Months Ending  
    2026     2025     2026     2025  
Numerator:                        
Net loss /income   $ (10,335,792 )   $ (93,837 )   $ (714,455 )   $ 259,001  
Dividends     (77,050 )     -       (77,050 )     -  
Total Numerator   $ (10,412,842 )   $ (93,837 )   $ (791,505 )   $ 259,001  
Denominator:                                
Weighted-average shares of common stock     42,639,875       6,953,265       64,921,095       7,039,144  
Dilutive effect of RSU’s     -       -       -       83,461  
Dilutive effect of Warrants     -       -       -       75,000  
Diluted weighted average of common stock     42,639,875       6,953,265       64,921,095       7,197,605  
Net loss per common share from:                                
Basic   $ (0.24 )   $ (0.01 )   $ (0.01 )   $ 0.04  
Diluted   $ (0.24 )   $ (0.01 )   $ (0.01 )   $ 0.04  

 

Risks and Uncertainties

 

The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide along with local, state, and federal governmental policy decisions. Several factors beyond the Company’s control could cause fluctuations in these conditions. Adverse conditions may include but are not limited to, general consumer demand, and new regulations imposed by the FDA. These adverse conditions could affect the Company’s consolidated financial condition and the results of its operations.

 

11

 

 

3. Cash

 

Cash consists of liquid funds and deposits in transit.

 

    September 30,
2026
    December 31,
2025
 
Cash   $ 227,770     $ 2,724,432  
Deposits in transit     4,130       2,264  
Total Cash   $ 231,900     $ 2,726,696  

 

4. Accounts Receivable

 

Accounts receivable consists of trade receivables, net of allowance for doubtful accounts.

 

    September 30,
2026
    December 31,
2025
 
Accounts receivable   $ 298,965     $ 518,474  
Allowance for doubtful accounts     -       -  
Accounts receivable, net   $ 298,965     $ 518,474  

 

As of September 30, 2026 and December 31, 2025, management determined that expected credit losses were not material and that no allowance for credit losses was required. In making this determination, management considered the Company’s historical loss experience, which has been minimal; the aging of outstanding balances, of which approximately 97% were current as of September 30, 2026; cash collected subsequent to period end; and the credit standing of the Company’s significant customers, including one customer that represented approximately 63% of accounts receivable as of September 30, 2026. Management also considered current economic conditions and reasonable and supportable forecasts. There were no write-offs or recoveries during the nine months ended September 30, 2026. Management evaluates the allowance on a quarterly basis.

 

5. Inventories

 

Inventories consisted of raw materials (minerals – magnesium, calcium, vitamins, botanical extracts), finished goods (capsules, tablets, powders, and creams) and packaging and supplies (bottles, labels, covers, filters, tipping paper and packaging materials).

 

    September 30,
2026
    December 31,
2025
 
Raw materials   $ 532,673     $ 507,693  
Packaging, supplies & other     133,109       141,320  
Finished goods     1,050,025       911,470  
Allowance for inventory obsolescence     (2,207 )     (10,972 )
Total inventories, net   $ 1,713,600     $ 1,549,511  

 

The Company reviews the allowance for inventory obsolescence on a quarterly basis and adjusted as necessary.

 

12

 

 

6. Prepaid Expenses and Other Current Assets

 

    September 30,
 2026
    December 31,
 2025
 
Prepaids & deposits   $ 267,981     $ 329,720  
Other current assets     -       63,279  
Total prepaids and other current assets   $ 267,981     $ 392,999  

 

Prepaid expenses consist of prepayments made to vendors as deposit and or retainers for professional services and insurance, and other current assets consists of refunds owed on insurance policies as well as reimbursement for professional fees.

 

7. Property and Equipment

 

Property and equipment consist of the following: The machinery and equipment owned by Kirkman allows the Company to carry out the entire production process in-house, from mixing raw materials to creating finished products, including encapsulation, labeling, and packaging.

 

    September 30,
 2026
    December 31,
 2025
 
Machinery & Equipment   $ 739,021     $ 739,021  
Computer Equipment     30,988       30,988  
Furniture & Fixtures     3,302       3,302  
Total property and equipment     773,311       773,311  
Less: Accumulated depreciation     (749,421 )     (735,932 )
Property and equipment, net   $ 23,890     $ 37,379  

 

Depreciation expense totaled $4,393 and $4,942 for the three months ended September 30, 2026 and 2025, respectively.

 

Depreciation expense totaled $13,489 and $15,990 for the nine months ended September 30, 2026 and 2025, respectively.

 

8. Right-of-Use Assets and Lease Liabilities

 

The Company maintains leases on a building and certain business equipment as detailed below. These obligations include the minimum lease payments as recognized on a straight-line basis over the lease term. The following are the expected payments on these leases as of September 30, 2026. The leases are considered “operating lease” and consequently lease payments are calculated on a straight-line basis, including the total amount of interest related.

 

The changes in the right-of-use assets are as follows:

 

    September 30,
 2026
    December 31,
 2025
 
Right of use assets:            
Right of use assets recognized as of January 1st   $ 1,667,693     $ 2,000,092  
Additions     -       -  
Amortization Expense     (269,870 )     (332,399 )
Right of use assets, net   $ 1,397,823     $ 1,667,693  

 

13

 

 

The changes in lease liabilities are as follows:

 

    September 30,
 2026
    December 31,
 2025
 
Lease liabilities recognized as of January 1st   $ 1,806,777     $ 2,136,032  
Additions     -       -  
Lease payments     (279,191 )     (329,255 )
Lease liabilities at period end     1,527,586       1,806,777  
Less: current portion     (384,181 )     (371,272 )
Long-term portion   $ 1,143,405     $ 1,435,505  

 

The following table presents information about the future maturity of the lease liabilities under the Company’s operating and financing leases as of September 30, 2026.

 

Maturity of Lease Liabilities   1. Operating Facility     2. Office Equipment     3. Office Equipment     Total
 Amount
 
2026   $ 122,222     $ 2,498     $ 89     $ 124,809  
2027     503,349       -       -       503,349  
2028     518,123       -       -       518,123  
2029     533,220       -       -       533,220  
2030     91,442       -       -       91,442  
Total future minimum lease payments     1,768,356       2,498       89       1,770,943  
Less: Imputed interest     (243,357 )     -       -       (243,357 )
Present value of lease liabilities   $ 1,524,999     $ 2,498     $ 89     $ 1,527,586  
Remaining lease term (in years)     3.42       0.08       0.08          

 

Right-of-use assets and lease liabilities comprise three leases.

 

Lease 1, Operating Facility

 

On January 1, 2023, the Company entered into a 7-year and 2-months lease for an industrial building encompassing approximately 24,400 square feet. This facility accommodates the sales and marketing, general and administrative, shipping department, and includes 9,663 square feet of production / manufacturing area. At inception of the lease, the Company recorded a right of use asset and liability. The Company used an effective borrowing rate of 9.0% within the calculation.

 

The base monthly rent is $28,957 per month, with subsequent annual increases of 3.0%. Operating expense came to $13,618 per month for the nine months ending September 30, 2026.

 

Leases 2 and 3, Equipment

 

Leases 2 and 3 are office equipment leases: four copiers under a five-year lease entered into on September 30, 2021, and an accessory under a lease entered into on March 14, 2022 with a term of four years and seven months. At inception of each lease, the Company recorded a right-of-use asset and liability using an effective borrowing rate of 9.0%. The combined base monthly payment in 2026 is $2,587 ($2,498 and $89, respectively), with no annual increase on the accessory lease.

 

14

 

 

9. Intangible Assets and Goodwill

 

On July 3, 2019, the Company entered into an Asset Purchase Agreement (the “APA”) with the Kirkman Group Inc. and David Humphrey (collectively, “Kirkman”) to acquire certain tangible and intangible assets for a purchase price of $5,000,000.

 

The excess of purchase consideration over the fair value of net assets acquired was recorded as goodwill.

 

The Kirkman brand and the cGMP certification were assigned an indefinite useful life, whereas the customer relationships were assigned a life span of 10 years.

 

The following table summarizes the remaining fair value of assets acquired and liabilities assumed from the acquisition of Kirkman in July 2019.

 

    September 30,
 2026
    December 31,
 2025
 
Kirkman brand, net   $ 925,700     $ 925,700  
cGMP certification     310,000       310,000  
Customer relationships     461,300       461,300  
Total intangible assets, gross     1,697,000       1,697,000  
Less: Accumulated amortization: Customer relationships     (334,186 )     (299,589 )
Intangible assets, net   $ 1,362,814     $ 1,397,411  

 

The following table presents the amortization for the remaining useful life of the customer relationships:

 

2026   $ 11,533  
2027     46,130  
2028     46,130  
2029     23,321  
Total   $ 127,114  

 

Goodwill

 

    September 30,
 2026
    December 31,
 2025
 
    $ 818,139     $ 818,139  

 

Impairment Assessment

 

Goodwill and indefinite-lived intangible assets are tested for impairment annually as of December 31, and between annual tests when events or changes in circumstances indicate that it is more likely than not that the asset is impaired. Customer relationships, a finite-lived intangible asset, are tested for recoverability when events or changes in circumstances indicate that the carrying amount may not be recoverable.

 

During the nine months ended September 30, 2026, management identified the following as indicators of potential impairment: the decline in the Company’s share price and market capitalization; the delisting of its common stock from the Nasdaq Capital Market in June 2026; the events of default under the Series C Convertible Preferred Shares and Senior Secured Convertible Notes (Notes 16 and 19); and the substantial doubt about the Company’s ability to continue as a going concern (Note 2).

 

Accordingly, Management performed an assessment as of September 30, 2026. In its assessment, management considered the Kirkman business’s revenue, which was consistent with forecast, and its gross margin, which improved to 59% from 54%. It also considered industry conditions, the continued use of the Kirkman brand, cGMP certification and customer relationships, and the Company’s market capitalization adjusted for obligations held at the parent company level. Based on this assessment, management concluded that goodwill and intangible assets were not impaired, and no impairment was recognized for the three and nine months ended September 30, 2026 or the year ended December 31, 2025.

 

These estimates require significant judgment, including assumptions about future revenue, margins, royalty rates, discount rates and terminal growth rates. It is reasonably possible that these estimates could change materially in the near term. Further declines in sales, the loss of a significant customer, an increase in discount rates, adverse developments relating to the events of default, or a sale of the Kirkman business at a price below its carrying amount could result in impairment charges, which could be material.

 

15

 

 

10. Accounts Payable and Accrued Liabilities

 

The Company’s accounts payable consist of obligations that are payable to vendors and other third parties in the normal course of business operations, as well as dividends payable to investors, and its accrued liabilities and accrued compensation are comprised of accrued expenses for consulting, advisory services, professional, audit services and equity awards earned but not yet issued and settlement expense.

 

    September 30,
 2026
    December 31,
 2025
 
Accounts payable   $ 986,564     $ 668,220  
Accrued liabilities     1,239,876       838,121  
Accrued compensation - shares earned but not issued     330,160       47,902  
Total accounts payable and accrued liabilities   $ 2,556,599     $ 1,554,243  

 

11. Lines of Credit

 

On August 19, 2025, the Company entered into two lines of credit agreements with a third-party whereby the Company received a total of $26,354. The term of the loans were for six months, with a 9% contract interest rate. The loans were repaid in Feb 2026.

 

    September 30,
 2026
    December 31,
 2025
 
Line of credit recognized as of January 1   $ 8,109     $ 32,235  
Proceeds from debt facilities     -       99,733  
Payments on debt facilities     (8,109 )     (123,859 )
Line of credit as of period end     -       8,109  
Less: current portion     -       (8,109 )
Long-term portion   $ -     $ -  

 

12. SBA Loan Payable

 

On July 7, 2020, Kirkman applied for and was granted a thirty (30) year loan from the U.S. Small Business Administration (“SBA”) for $150,000 with an interest of 3.75% per annum accrued daily. The SBA loan was obtained, to alleviate the financial burden as a result of the COVID-19 pandemic.

 

    September 30,
 2026
    December 31,
 2025
 
SBA loan due as of January 1   $ 140,468     $ 143,904  
Proceeds from SBA loan     -       -  
Payments on SBA loan     (2,688 )     (3,436 )
SBA loan due at period end     137,780       140,468  
Less: current portion     (3,668 )     (3,595 )
Long-term portion   $ 134,112     $ 136,873  

 

16

 

 

The Company has the following SBA loan future commitments as of September 30, 2026.

 

    Amount  
2026   $ 907  
2027     3,702  
2028     3,830  
2029     3,990  
2030     4,117  
2031 and beyond     121,234  
Total   $ 137,780  

 

13. Loans Payable, Related Party

 

On March 11, 2024, the Company executed a loan agreement with a related party in the amount of $130,000, with an annual interest rate of 20% and a due date of March 11, 2031.

 

On March 10, 2025, the Company executed a loan agreement with a related party in the amount of $225,000, with an annual interest rate of 18% and a due date of March 7, 2029.

 

    September 30,
 2026
    December 31,
 2025
 
Loans payable, related party as of January 1   $ 306,151     $ 370,703  
Loan agreement executed with related party during the periods     -       225,000  
Reclass to loans payable     -       (247,634 )
Payments to related party     (45,158 )     (41,918 )
Loans payable, related party as of period end     260,993       306,151  
Less: current portion     (70,709 )     (61,642 )
Long-term portion   $ 190,284     $ 244,509  

 

14. Loans Payable

 

In December 2023, the Company entered into a short-term debt facility with an officer and director of the parent company, Hemptown Organics Corp., whereby the Company received a non-interest-bearing loan in the amount of $247,634. As of September 30, 2026, $129,603 was still outstanding. The officer and director resigned in January 2025, and therefore the loan was reclassed from related party to loans payable.

 

On August 29, 2025 the Company entered into a loan agreement with a third party whereby the Company received approximately $95,277. The terms of the loan were for 10 months, with a 7.5% interest rate over the term of the loan

 

On November 5, 2025 the Company entered into a loan agreement with a third party whereby the Company received approximately $169,048. The terms of the loan are for 10 months, with a 7.0% interest rate over the term of the loan.

 

On September 30, 2026, the Company entered into a loan agreement with a third party whereby the Company received approximately $32,707. The terms of the loan are for 10 months, with a 7.95% interest rate over the term of the loan.

 

    September 30,
 2026
    December 31,
 2025
 
Loan payables as of January 1   $ 402,650     $ 171,500  
Loan agreement executed during the periods     32,707       364,325  
Reclass to loan payable     -       247,634  
Payments to loan payable     (273,047 )     (380,809 )
Loan payable as of year-end     162,310       402,650  
Less: current portion     (162,310 )     (402,650 )
Long-term portion   $ -     $ -  

 

17

 

 

15. Derivative Liability

 

Series A & B

 

On November 5, 2025, the Company issued 100,000 shares of Series A preferred stock and 80,000 shares of Series B preferred stock, each with a stated value of $100 per share. The embedded conversion features did not qualify for equity classification under ASC 815 and were bifurcated and recorded as derivative liabilities at fair value on the date of issuance, determined using a Monte Carlo simulation model, with the residual proceeds allocated to the preferred stock host instruments. The derivative liabilities were remeasured to fair value immediately prior to each conversion, share buyback and the March 9, 2026 exchange (see Note 19) and were derecognized at their carrying amounts.

 

Revaluation at Period End

 

The derivative liabilities are remeasured to fair value at each reporting date, with changes in fair value recognized in earnings as follows:

 

Level 3 Roll-forward

 

    September 30, 2026     December 31, 2025  
    Series A     Series B     Total     Series A     Series B     Total  
Beginning balance   $ 3,270,370     $ 36,375     $ 3,306,745     $ -     $ -     $ -  
Initial recognition of derivative liability upon issuance     -       -       -       11,443,814       1,850,428       13,294,242  
Change on revaluation of fair value of derivative liability     190,600       15,862       206,462       (6,736,673 )     (622,262 )     (7,358,935 )
Derecognition upon conversions     -       (9,734 )     (9,734 )     (60,996 )     (1,191,791 )     (1,252,787 )
Derecognition upon share buybacks     (465,433 )     -       (465,433 )     (1,375,775 )     -       (1,375,775 )
Derecognition upon exchange     (2,995,537 )     (42,503 )     (3,038,040 )                        
Ending balance   $ -     $ -     $ -     $ 3,270,370     $ 36,375     $ 3,306,745  

 

The derivative liabilities are classified within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs. The Company utilized a Monte Carlo simulation model incorporating the following key assumptions at the date of exchange. The Company estimated fair value using a Monte Carlo simulation model, which simulates the Company’s common stock price over the expected term and applies the contractual conversion terms of the Series A and Series B preferred stock. The key assumptions used at the date of exchange and at December 31, 2025 are presented below.

 

The significant unobservable inputs are expected volatility, expected term and the probability of a dilutive financing. The common stock price, risk-free interest rate and dividend yield are observable inputs.

 

Input   At Exchange     31-Dec-25  
Common stock price   $ 0.20     $ 0.19  
Expected volatility     80.00 %     53.02 %
Risk-free interest rate     2.44 %     2.55 %
Dividend yield     0.00 %     0.00 %
Expected term in years     0.67       0.85  
Probability of dilutive financing     50.00 %     50.00 %

 

Series C

 

On March 9, 2026, the Company exchanged all issued and outstanding Series A and Series B preferred stock for Series C Convertible Preferred Stock (the “Series C Preferred”), Senior Secured Convertible Promissory Notes (the “Convertible Notes”) and cash consideration (see Notes 16 and 19). The Series C Preferred is classified as a liability under ASC 480-10-25-14. The embedded conversion features of the Series C Preferred and the Convertible Notes are not clearly and closely related to their host instruments and do not qualify for the scope exception in ASC 815-40. They were therefore bifurcated and recorded as derivative liabilities at fair value on the date of issuance, determined using a Monte Carlo simulation model. The derivative liabilities are presented as a separate line item on the consolidated balance sheet and are remeasured at fair value at each reporting date, with changes in fair value recognized in earnings.

 

18

 

 

Level 3 Roll-forward

 

      September 30, 2026       December 31, 2025  
      Series C
Preferred Stock
      Series C
Convertible Note
      Series C
Total
      Series C
Preferred Stock
      Series C
Convertible Note
      Series C
Total
 
Beginning balance   $ 972,348     $ 209,598     $ 1,181,946     $ -     $ -     $ -  
Change on revaluation of fair value of derivative liability     (31,367 )     186,161       154,794       -       -       -  
Ending balance   $ 940,981     $ 395,759     $ 1,336,740     $ -     $ -     $ -  

 

The derivative liabilities are classified within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs. The Company utilized a Monte Carlo simulation model incorporating the following key assumptions as of September 30, 2026:

 

Input   September 30,
2026
   

June, 30

2026

 
Common stock price   $ 0.0046     $ 0.16  
Expected volatility     134.00 %     80.00 %
Risk-free interest rate     4.60 %     3.56 %
Dividend yield     0.00 %     0.00 %
Expected term in year     1.0       0.94 – 0.97  
Probability of dilutive financing     50.00 %     50.00 %

 

16. Convertible Note

 

On March 9, 2026, in connection with the Exchange and Amendment Agreement (the “Exchange Agreement”) entered into among the Company and the holders of the Company’s Series A Convertible Preferred Stock and Series B Convertible Preferred Stock, the Company issued senior secured convertible promissory notes (collectively, the “Notes”) with an aggregate original principal amount of $837,800 to four institutional investors. The Notes were issued as partial consideration for the exchange and cancellation of the Company’s outstanding Series A and Series B Convertible Preferred Stock, together with shares of newly designated Series C Convertible Preferred Stock, shares of common stock, and cash. No new cash proceeds were received by the Company with respect to the issuance of the Series C Convertible Preferred Stock or the Notes.

 

Principal Terms of the Notes

 

The Notes have substantially identical terms. They mature on August 9, 2027 and bear interest at 12% per annum, payable at maturity, increasing to 24% per annum upon an Event of Default. Beginning one year after the issue date, the Company is required to repay the original principal in six equal monthly installments, in cash or, subject to certain equity conditions, in shares of common stock, with any remaining balance due at maturity. The Notes are senior secured obligations, secured by a first priority security interest in substantially all of the Company’s assets, and may be prepaid at 100% of outstanding principal plus accrued interest on five business days’ notice. Each holder may convert at 120% of the closing trading price on the trading day immediately prior to the Exchange Date (the “Fixed Conversion Price”), subject to full-ratchet anti-dilution protection and a 4.99% beneficial ownership limitation (which a holder may increase to 9.99% on 61 days’ notice). Events of Default include failure to pay principal or interest when due, delisting of the common stock from a national securities exchange, failure to maintain reporting compliance under the Exchange Act and cross-default with other Company indebtedness. Upon an Event of Default, the conversion price becomes 85% of the lowest traded price over the preceding ten trading days, outstanding obligations increase to 125%, interest accrues at the default rate, the Company incurs a $5,000 monthly monitoring fee, and the holders may accelerate the Notes. The Notes also contain customary affirmative and negative covenants.

 

Accounting Treatment

 

The Notes are accounted for as debt under ASC 470 and are subsequently measured at amortized cost using the effective interest method. The embedded conversion feature is not clearly and closely related to the debt host and does not meet the fixed-for-fixed criterion in ASC 815-40. It was therefore bifurcated and recorded as a derivative liability at fair value, determined using a Monte Carlo simulation, and is remeasured at each reporting date, with changes in fair value recognized in other income (expense).

 

19

 

 

Carrying Value and Activity

 

The following table summarizes the components of the Notes and the related embedded derivative liability as of September 30, 2026:

 

    Notes
Payable
    Embedded
Derivative
Liability
 
Issuance — March 9, 2026   $ 837,800     $ 214,075  
Conversions     (1,628,896 )     (263,728 )
Principal adjustments     1,135,915       183,912  
Liability with conditional timing consolidation     450,000       72,858  
Default     198,705       -  
Change in fair value     -       188,643  
Balance — September 30, 2026   $ 993,525     $ 395,760  

 

Pursuant to the Conversion Price Reduction and Waiver agreement dated May 11, 2026, between the Company and the convertible note holders, any cash consideration outstanding as the effective date (as defined in the Exchange Agreement) was consolidated and added to and capitalized as additional principal under each applicable Holder’s existing senior secured convertible promissory note issued pursuant to the Exchange Agreement.

 

The Notes are presented as current debt on the condensed consolidated balance sheet as of September 30, 2026, as the first scheduled amortization payment is due not more than twelve months after the balance sheet date. The embedded derivative liability is presented within derivative liabilities on the condensed consolidated balance sheet.

 

For the three and nine months ended September 30, 2026, the Company recognized interest expense of approximately $60,936 and $105,779 in respect of the Notes. The Company recognized a loss of $186,161 and $188,643 in connection with the change in fair value of the embedded derivative liability for the three and nine months ended September 30, 2026, which is included in other income (expense), net.

 

Future Principal Payments

 

The aggregate scheduled principal payments under the Notes as of September 30, 2026 are as follows:

 

Year Ending December 31,   Amount  
2026   $ —  
2027     993,525  
Total   $ 993,525  

 

Fair Value Measurements

 

The fair value of the bifurcated embedded derivative liability is classified within Level 3 of the fair value hierarchy under ASC 820, as its valuation requires significant unobservable inputs, including expected volatility of the Company’s common stock and probability-weighted estimates of the timing and method of conversion. See Note 13 for measurement details.

 

17. 2026 Equity Incentive plan

 

In May 2026, the shareholder’s’ approved 4,000,000 (four million) shares of our Common Stock for issuance under the Plan. The Plan includes an evergreen provision providing for an automatic annual increase in the shares of Common Stock available for issuance under the Plan beginning in the 2027 fiscal year of the Company in an amount equal to the least of (a) 500,000 shares, (b) a number equal to five percent (5%) of the total number of shares of Common Stock outstanding on December 31st of the preceding calendar year or (c) such number of shares as shall be determined by the Plan administrator.

 

On June 29, 2026 the Company granted the CEO 3,500,000 fully vested incentive stock options at $0.0055.

 

20

 

 

18. Stock-based Compensation

 

The Company accounts for stock-based compensation in accordance with ASC 718, Compensation—Stock Compensation. Awards granted to executives, employees, directors, and non-employees — consisting primarily of restricted stock units (“RSUs”) — are measured at grant-date fair value and recognized as expense in the consolidated statements of operations on a straight-line basis over the requisite service period, with forfeitures recognized as they occur. Awards subject to performance conditions are expensed when achievement of the underlying condition is considered probable, and awards subject to market conditions are expensed over the derived service period regardless of whether the condition is ultimately achieved. Fair value is determined by reference to the closing price of the Company’s common stock on the grant date for awards granted following the Company’s Nasdaq listing, and by reference to the share price established in the most recent Section 409A valuation report prepared by an independent third-party appraiser for awards granted prior to listing.

 

During the nine months ended September 30, 2026, and 2025, the Company recorded general and administrative expense of $437,973 and $598,856, respectively, in its consolidated statements of operations, with respected to RSUs granted.

 

19. Common and Preferred Stock

 

On January 21, 2025, the Company effected a reverse stock split of its authorized common stock on 1-for-18.338622 basis. The authorized capital stock of the Company remained unchanged. All references to share and per share amounts in the consolidated financial statements and accompanying notes thereto have been retroactively restated to reflect the reverse stock split.

 

All shares of Common Stock are entitled to one vote with respect to each common share held at all meetings of shareholders of the Company.

 

Preferred Stock

 

Summary of Significant Transactions

 

During the nine months ended September 30, 2026, the Company’s capital structure changed significantly as a result of the following transactions:

 

● Exchange of Series A and Series B Preferred Stock. On March 9, 2026, the Company exchanged all outstanding Series A and Series B Preferred Stock for Series C Preferred with an aggregate stated value of $6,032,000, Convertible Notes with an aggregate principal amount of $837,800, 5,190,171 Common Stock Consideration Shares, and cash consideration of approximately $900,000.

 

● Conversion price reduction. On May 11, 2026, the Company entered into a Conversion Price Reduction and Waiver Agreement. The agreement reduced the Series C conversion price to $0.1636 per share and capitalized the remaining $450,000 of cash consideration as additional principal under the Convertible Notes.

 

● Conversions. Holders converted Series C Preferred with an aggregate stated value of $3,268,000 and Convertible Notes with an aggregate principal amount of $1,628,896 into common stock, respectively.

 

● Warrant exercise. A lender exercised warrants to purchase 37,500 shares of common stock and received 5,480,645 shares of common stock.

 

As a result of these transactions, common shares outstanding increased from 18,704,649 at December 31, 2025 to 64,921,095 at September 30, 2026. As described below, the Series C Preferred and the Convertible Notes are classified as liabilities, and the Company is in default under both instruments.

 

Exchange and Amendment Agreement

 

On March 9, 2026, the Company entered into an Exchange and Amendment Agreement with holders of its outstanding Series A and Series B Preferred Stock. Pursuant to the agreement, the Company exchanged all issued and outstanding Series A and Series B Preferred Stock for a combination of:

 

● Series C Convertible Preferred Stock (the “Series C Preferred”);

 

● Senior Secured Convertible Promissory Notes (the “Convertible Notes”); and

 

● Cash consideration.

 

21

 

 

The transaction resulted in the legal extinguishment of the Series A and Series B Preferred Stock and the issuance of new financial instruments.

 

Extinguishment of Series A and B Preferred Stock

 

The Company accounted for the exchange as an extinguishment of the Series A and Series B Preferred Stock. The extinguishment was measured as the difference between:

 

● The carrying amount of the Series A and Series B Preferred Stock (including associated derivative liabilities), and

 

● The fair value of the consideration transferred.

 

As a result, the Company recognized a loss on extinguishment of approximately $6.9 million in the consolidated statement of operations for the nine months ended September 30, 2026.

 

Prior to extinguishment, derivative liabilities associated with the Series A and Series B Preferred Stock were remeasured to fair value, with changes recognized in earnings.

 

Series C Convertible Preferred Stock

 

Although the Series C Preferred is legally structured as equity, it represents an obligation to settle a fixed monetary amount through a variable number of shares and is therefore classified as a liability in accordance with ASC 480-10-25-14. Its embedded conversion features are not clearly and closely related to the host instrument and do not qualify for the scope exception for contracts indexed to and settled in the Company’s own stock. They are bifurcated and recognized as derivative liabilities at fair value upon issuance, with subsequent changes in fair value recognized in earnings (see Note 15).

 

Mandatory Redemption; Covenant Non-Compliance

 

The Series C is subject to mandatory redemption (forced amortization) under its Certificate of Designations, in twelve equal monthly installments of $230,333 (the aggregate stated value of $2,764,000 divided by twelve), beginning on or about June 8, 2026 and payable, at the Company’s election, in cash or, subject to the satisfaction of equity conditions, in shares of common stock. During the nine months ended September 30, 2026, holders converted Series C with an aggregate stated value of $3,268,000 into shares of common stock. The Company did not commence the mandatory redemption and made no redemption installment, in cash or in shares, through the date of this report, which constitutes an Event of Default as described below. The outstanding stated value of the Series C of $2,764,000 is classified as a current liability. The Company is in discussions with the holders to negotiate the terms, and no holder has given notice of an event of default or exercised acceleration or cross-default rights as of the date of this report.

 

Events of Default and Related Accounting

 

Series C mandatory redemption. The Company’s Series C Convertible Preferred Shares (the “Series C”), issued March 9, 2026 and accounted for as a debt host instrument with a bifurcated embedded conversion derivative, are subject to a mandatory redemption provision requiring the Company to begin redeeming the Series C in equal monthly installments beginning on or about June 8, 2026. The Company did not commence the mandatory redemption and made no redemption installment during the three months ended September 30, 2026. The Company has concluded that its failure to commence the mandatory redemption constitutes an Event of Default under the Series C and the Company’s Senior Secured Convertible Notes (the “Notes”), with an event-of-default date of June 8, 2026.

 

Concurrent listing event of default. Separately, on June 16, 2026 the Company’s common stock ceased trading on the Nasdaq Capital Market and began trading in the over-the-counter market, following a Nasdaq staff delisting determination. The failure to maintain a listing on a national securities exchange constitutes a separate and independent Event of Default under the Notes.

 

22

 

 

Effect on the instruments. As a result of the Events of Default, and from the applicable event-of-default date: (i) the dividend rate on the Series C increased from 0% to 24% per annum, which, given the debt classification of the Series C, the Company recognizes as interest expense; (ii) the outstanding obligations under the Notes increased to 125% of the amounts otherwise outstanding under the default-premium provisions; (iii) interest on the Notes accrues at the 24% default rate; (iv) the Company became obligated for a monthly monitoring fee of $5,000; and (v) the conversion price applicable to the Series C and the Notes became the alternate conversion price (85% of the lowest trading price over a ten-trading-day lookback), which the Company reflected in the remeasurement of the embedded conversion derivatives at September 30, 2026.

 

Remedies and status. The Events of Default afford the holders various rights and remedies, including the right to accelerate the Notes and to exercise the default remedies described above. As of the date of this report, no holder had accelerated the Notes or the Series C. The Company is in discussions with the holders.

 

Convertible Notes

 

The Convertible Notes are accounted for as debt instruments in accordance with ASC 470. Their embedded conversion features are not clearly and closely related to the debt host and do not qualify for the scope exception for contracts indexed to and settled in the Company’s own stock. They are bifurcated from the host debt instrument and accounted for as derivative liabilities at fair value, with subsequent changes in fair value recognized in earnings (see Note 16).

 

Common stock

 

Classification

 

The Common Stock Consideration Shares (including the portion represented by Blocker Holdback Shares) are classified as permanent equity. Under ASC 480, the shares (i) are not mandatorily redeemable, (ii) carry no obligation for the Company to repurchase its equity, and (iii) do not represent an obligation to issue a variable number of shares — the share count is fixed as of the Exchange Date based on the Market Price determined on that date and does not vary with subsequent changes in fair value, a fixed monetary amount, or movements inversely related to the Company’s shares.

 

Blocker Holdback Shares are presented within stockholders’ equity as “Common stock to be issued.” The 4.99% beneficial ownership limitation operates as a delivery mechanic that defers physical issuance of a fixed number of shares; it does not alter the Holders’ entitlement. Accordingly, no remeasurement is required, and the obligation does not require liability or derivative classification under ASC 815-40. Upon physical delivery, amounts are reclassified to common stock (at par) and additional paid-in capital.

 

The shares were measured at fair value on the Exchange Date based on the quoted market price of the Common Stock (Level 1 of the ASC 820 fair value hierarchy) and included as a component of the consideration transferred in measuring the loss on extinguishment of the Series A and Series B Preferred Stock.

 

Features

 

Aggregate shares

 

5,190,171 Common Stock Consideration Shares allocated among the four Holders in accordance with Schedule A to the Exchange Agreement.

 

Beneficial Ownership Limitation

 

Issuance is capped at 4.99% of the outstanding Common Stock for any Holder (together with its affiliates). Shares that cannot be physically issued at closing without breaching the cap are automatically reduced and treated as Blocker Holdback Shares, issuable on a fixed-share basis upon written request once the Holder’s ownership permits delivery. The Company has no right to substitute cash or other consideration.

 

23

 

 

Deferred Cash Consideration

 

As part of the Exchange and Amendment Agreement entered into on March 9, 2026, the Company agreed to pay aggregate cash consideration of approximately $900,000 to holders of the exchanged Series A and Series B Preferred Stock.

 

● A total of $450,000 was paid at closing; and

 

● The remaining $450,000 is payable upon the earlier of the effectiveness of a registration statement related to the Company’s equity line of credit (“ELOC”), but in no event later than 90 days following the closing date.

 

On May 11, 2026 the Company and the Note Holders entered into a Conversion Price Reduction and Waiver Agreement, whereby the remaining $450,000 in cash consideration was consolidated and added to and capitalized as additional principal under each applicable Holder’s existing senior secured convertible promissory note issued pursuant to the Exchange Agreement.

 

If the Company does not have sufficient cash to satisfy the full payment at that time, any shortfall is required to be paid in six equal monthly installments.

 

Accounting Treatment

 

The Company evaluated this obligation under ASC 450, Contingencies, and ASC 405, Liabilities and determined that the obligation to pay the remaining $450,000 is probable and estimable, as it represents a contractual commitment arising from the exchange transaction, therefore the Company recognized the obligation as a liability at the transaction date.

 

Presentation

 

The liability is included within:

 

● Liability with conditional timing (or current liabilities) as of September 30, 2026.

 

Issued Warrants

 

    Number of
warrants
    Weighted-Average
Exercise
 Price
per Share
    Weighted-Average
Remaining Life
 
Outstanding at December 31, 2025     205,000     $ 8.5       4.60 years  
Granted     -       -       -  
Exercised     (37,500 )     -       -  
Outstanding at September 30, 2026     167,500     $ 8.33       4.03 years  
Exercisable at September 30, 2026     167,500     $ 8.33       4.03 years  
Intrinsic value at September 30, 2026     -       -       -  

 

On March 10, 2025, the Company issued a lender a warrant for the purchase of 37,500 shares of common stock at an exercise price of $8.50 per share. The warrants carry a term of 5 years and are exercisable in whole or in part at any time or times during the exercise period. The warrants were valued at $23,138 using a Black-Scholes pricing model.

 

On June 1, 2025, the Company issued a lender a warrant for the purchase of 37,500 shares of common stock at an exercise price of $8.50 per share. The warrants carry a term of 5 years and are exercisable in whole or in part at any time or times during the exercise period. The warrants were valued at $22,125 using a Black-Scholes pricing model.

 

On November 5, 2025, the Company issued finder warrants for the purchase of 80,000 shares of common stock at an exercise price of $8.50 per share. The warrants carry a term of 5 years and are exercisable in whole or in part at any time or times during the exercise period. The warrants were valued at $46,800 using a Black-Scholes pricing model.

 

On November 17, 2025, the Company issued a lender a warrant for the purchase of 50,000 shares of common stock at an exercise price of $8.50 per share. The warrants carry a term of 5 years and are exercisable in whole or in part at any time or times during the exercise period. The warrants were valued at $150 using a Black-Scholes pricing model.

 

For the nine months ended September 30, 2026, the lender exercised 37,500 warrants and receive 5,480,645 shares of the Company’s common stock.

 

24

 

 

20. Segment Reporting

 

The Company historically operated through two operating segments:

 

(1) Kirkman, which sold a range of nutraceuticals, supplements and related products; and

 

(2) HT Naturals, which sold a range of hemp-based consumer products.

 

As of March 31, 2026 the Company ceased the operations of HT Naturals and wound down its hemp-based consumer products business. Following the closure, the Company’s continuing operations consist solely of the Kirkman business.

 

The Company has a corporate function, which is not an operating segment and includes expenses related to corporate management and administration, including legal, audit, accounting, tax, SEC reporting, and investor and public relations, among other corporate expenses.

 

The Company follows ASC 280, Segment Reporting, as amended by ASU 2023-07. The Company’s chief operating decision maker (the “CODM”) is its Chief Executive Officer.

 

As a result of the closure of HT Naturals, the CODM reviews financial information and makes operating decisions, including the allocation of resources and the assessment of performance, on a consolidated basis. Accordingly, effective with the closure of HT Naturals during the quarter, the Company has determined that it operates as a single operating segment and a single reportable segment. Prior period segment information has been recast to conform with the current period presentation.

 

The CODM uses consolidated net income (loss) as reported in the Company’s condensed consolidated statements of operations as the measure of segment profit or loss for purposes of assessing performance and deciding how to allocate resources. The significant expense categories and amounts regularly provided to the CODM are those presented on the face of the condensed consolidated statements of operations, including cost of sales, sales and marketing, general and administrative, and research and development expenses. The measure of segment assets is reported on the condensed consolidated balance sheets as total consolidated assets.

 

Substantially all of the Company’s long-lived assets are located in the United States, and substantially all of the Company’s revenues are generated from customers located in the United States.

 

Entity-Wide Disclosures

 

Geographic Revenue Information

 

For the nine months ended September 30, 2026 and 2025, 95% and 93% respectively of the Company’s net sales were generated in North America.

 

21. Revenue, net

 

This table shows revenue by product type:

 

    September 30,  
    2026     2025  
Nutraceutical (supplements)   $ 5,154,858     $ 4,996,424  
Hemp derived products     6,267       120,539  
Total revenue by product type   $ 5,161,125     $ 5,116,963  

 

As of March 31, 2026, the Company ceased the operations of HT Naturals and wound down its hemp-based consumer products business.

 

25

 

 

22. Concentration

 

For the nine months ended September 30, 2026 sales to two customers represented 26% and 3% for a total of 29% of sales totaling approximately $1,520,288. For the nine months ended September 30, 2025, sales to two customers represented 30% and 25% for a total of 55% of sales totaling $2,836,726.

 

23. Other Income / (expenses)

 

Other expense increased to $8,017,827 for the nine months ended September 30, 2026 from other income of $171,986 during the comparable prior year period. This decrease of $8,189,813 was primarily due to a decrease in other income which was the result of an Employee Retention Tax Credit (“ERTC”) reimbursement of $419,947, decrease in interest income received on the ERTC of $71,854, a loss on issuance of preferred stock of $6,310,464, a change of fair value of derivative liability of $1,097,362, an increase in other expense of $50,000, loss on issuance of preferred stock of $198,705 and an increase in interest expense of $48,353.

 

24. Commitments and Contingencies

 

The Company has an exclusive license agreement with Trailer Park Boys Incorporated (“TPB”) to market and sell hemp derived products. This license was effective as of July 21, 2021, expired on December 31, 2025, and has been subject to several amendments (the “TPB License”). Under the TPB License, the Company is obligated to pay TPB a total of minimum cash payments over the life of the TPB License of $725,000 and is obligated to issue to the TPB 14,440 shares of common stock of the Company.

 

As of September 30, 2026, the Company was engaged in a contractual dispute with TPB concerning the TPB License. The Company asserts that TPB has not fulfilled certain material obligations under the TPB License and, as a result, disputes the remaining $150,000 minimum cash payments. The Company has not accrued for any legal fees for the disputed amount mentioned above as management believes a loss is not probable at this time in accordance with ASC 450, Contingencies.

 

True Health Litigation

 

On July 14, 2026, the Circuit Court for the Eighteenth Judicial Circuit, DuPage County, Illinois entered a final order and judgment in favor of the HTO Parties on all counts in the previously disclosed litigation brought by True Health Medical Center, S.C. (“True Health”), finding that no royalties are due from the HTO Parties under the royalty agreement. The court entered judgment of $68,271 (unpaid royalties and interest) against Kirkman Group, Inc., the seller of certain assets to the HTO Parties and a separate legal entity. All claims against the individual defendants were resolved in their favor. The time to appeal has not expired. Because no amounts were awarded against the HTO Parties, the Company did not record any liability with respect to this matter.

 

25. Subsequent Events

 

The Company evaluated subsequent events and transactions that occurred after the balance sheet date through the date the consolidated financial statements were issued. Based on this evaluation, the Company did not identify any subsequent events that would have required recognition or disclosure in the consolidated financial statements.

 

26

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes and other financial information appearing elsewhere in this Quarterly Report on Form 10-Q. References to “Note” are to the notes included in our unaudited consolidated financial statements appearing elsewhere in this Quarterly Report.

 

Cautionary note regarding forward looking statements

 

This report contains forward-looking statements that can involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this report are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “can,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “future”, “goal,” “intend,” “may,” “outlook,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements contained in this report may include, but are not limited to, statements about:

 

● our goal and strategies;

 

● our future business development, financial condition and results of operations;

 

● expected changes in our revenue, costs or expenditures;

 

● growth of and competition trends in our industry;

 

● our expectations regarding demand for, and market acceptance of, our products;

 

● our expectations regarding our relationships with investors, institutional funding partners and other parties with whom we collaborate;

 

● fluctuations in general economic and business conditions in the markets in which we operate; and

 

● relevant government policies and regulations relating to our industry.

 

We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate, and financial trends that we believe may affect our business, financial condition, results of operations, and prospects, but these forward-looking statements are not guarantees of future performance or development. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained in this report, whether as a result of any new information, future events, or otherwise.

 

There are a number of risks, uncertainties, and other important factors that could cause our actual results to differ materially from the forward-looking statements contained in this report, including, among others, those factors set forth in the “Risk Factors” section of our Registration Statement on Form S-1, as amended, and may be subsequently updated by information in future annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Forms 8-K, filed with the Securities and Exchange Commission from time to time.

 

Overview

 

Our Company operates in the nutraceutical supplement industry. We are a manufacturer and distributor of supplements in categories such as pain, energy, prenatal, general health, bone and joint, gastro, immunity, cardiac, detox, mental clarity and focus, sleep, prenatal and urinary. Our end markets focus on end-consumers through different channels that include pharmacies, U.S. wholesalers, international distributors and direct-to-consumers sales. Our products are sold over the-counter, and consumers do not need a prescription to purchase our products.

 

27

 

 

Results of Operations

 

Comparison of the Three Months Ended September 30, 2026, to the Three Months Ended September 30, 2025

 

    Three Months Ended              
    September 30,     Change  
    2026     2025     Amount     Percentage  
Statements of Operations                        
Net revenue   $ 1,645,053     $ 1,694,174     $ (49,121 )     (3 )%
Cost of goods sold     684,289       715,824       (31,535 )     (4 )%
Gross profit     960,764       978,350       (17,586 )     (2 )%
Sales and marketing expenses     198,630       118,876       79,754       67 %
General and administrative expenses     1,076,896       937,762       139,134       15 %
Operating loss     (314,762 )     (78,288 )     (236,474 )     302 %
Other income / (expense)     (399,693 )     337,289       (736,982 )     (219 )%
Net loss   $ (714,455 )   $ 259,001     $ (973,456 )     (376 )%

 

Net Revenue

 

Net revenue for the three months ended September 30, 2026 was $1,645,053 compared to $1,694,174 for the three months ended September 30, 2025 representing a decrease of approximately 3%. This decrease of $49,121 in net revenue was primarily due to an increase in contract manufacturing of $27,004, a decrease in demand from our direct-to-consumer sales channel of $55,588, and a decrease in hemp derived products which was discontinued as of March 31, 2026.

 

Cost of goods sold

 

Cost of goods sold for the three months ended September 30, 2026 was $684,289 compared to $715,824 for the three months ended September 30, 2025 representing a decrease of approximately 4%. This decrease of $31,535 in cost of goods was primarily due to a decrease of $62,226 due to a decrease in products primarily sold for contract manufacturing and direct-to-consumer sales channel, decrease of $5,251 due to discontinuation of hemp derived products, an increase in product testing of $26,327, an increase in payroll and employee benefit expenses of approximately $4,012 and an increase in inventory shrinkage and obsolescence of $1,435.

 

Gross profit

 

Gross profit for the three months ended September 30, 2026 was $960,764 compared to $978,350 for the three months ended September 30, 2025 representing a decrease of 2%. This decrease of $17,586 was primarily due to a decrease in the demand from our direct-to-consumer sales channel, and discontinuation of sales of our hemp derived products of $76,495, an increase of sales for contract manufacturing of $27,004, and a decrease in cost of goods sold due to products primarily sold for contract manufacturing and the discontinuation of hemp product sales of $67,477, an increase in product testing of $26,327, an increase in payroll and employee benefit expenses of approximately $4,012 and an increase in inventory shrinkage and obsolescence of $1,435.

 

Sales and marketing expenses

 

Sales and marketing expenses for the three months ended September 30, 2026, were $198,630 compared to $118,876 for the three months ended September 30, 2025, representing an increase of approximately 67%. This increase of $79,754 was primarily due to an increase in Amazon referral fees of $98,322, an increase in advertising and promotional expenses of $23,173, a decrease in payroll and employee benefit expenses of $36,537, a decrease in professional fees of $11,854, and an increase of $6,783 for conference expenses.

 

General and administrative expenses

 

General and administrative expenses for the three months ended September 30, 2026 were $1,076,896, compared to $937,762 for the three months ended September 30, 2025, representing an increase of approximately 15%. This increase of $139,134 was primarily attributable to an increase in payroll and employee benefit expenses of approximately $218,379, an increase in Amazon seller fees of approximately $73,032, an increase in insurance premiums of $58,834, an increase in public company related expenses of $25,271, an increase in computer licenses and dues and subscriptions of 17,869, an increase in rent expense of 21,280, a decrease in professional fees of $230,095, and a decrease in stock-based compensation of $88,499.

 

28

 

 

Other income / (expenses)

 

Other income / (expense) for the three months ended September 30, 2026 were $399,693 compared to $337,289 for the three months ended September 30, 2025, representing a decrease of approximately 219%. This decrease of $736,982 was primarily due to a decrease in other income which was the result of an Employee Retention Tax Credit (“ERTC”) reimbursement of $419,947, decrease in interest income received of $71,386 which was primarily due to the ERTC, a change of fair value of derivative liability of $154,794, a decrease in change in fair value of derivative liabilities of $154,794, and an increase in interest expense of $90,855.

 

Comparison of the Nine months Ended September 30, 2026, to the Nine Months Ended September 30, 2025

 

    Nine Months Ended              
    September 30,     Change  
    2026     2025     Amount     Percentage  
Statements of Operations                        
Net revenue   $ 5,161,125     $ 5,116,963     $ 44,162       1 %
Cost of goods sold     2,118,887       2,303,752       (184,865 )     (8 )%
Gross profit     3,042,238       2,813,211       229,027       8 %
Sales and marketing expenses     802,721       462,545       340,176       74 %
General and administrative expenses     4,557,482       2,616,489       1,940,993       74 %
Operating loss     (2,317,965 )     (265,823 )     (2,052,142 )     772 %
Other income / (expense)     (8,017,827 )     171,986       (8,189,813 )     (4762 )%
Net loss   $ (10,335,792 )   $ (93,837 )   $ (10,241,995 )     10915 %

 

Net revenue

 

Net revenue for the nine months ended September 30, 2026 was $5,161,125 compared to $5,116,963 for the nine months ended September 30, 2025 representing an increase of approximately 1%. This increase of $44,162 in net revenue was primarily due to the increase in the demand from our direct-to-consumer sales channel of $107,342 an increase in contract manufacturing sales of $50,646, and a decrease in hemp derived sales of $114,272 which was discontinued as of March 31, 2026.

 

Cost of goods sold

 

Cost of goods sold for the nine months ended September 30, 2026 was $2,118,887 compared to $2,303,752 for the nine months ended September 30, 2025 representing a decrease of approximately 8%. This decrease of $184,865 in cost of goods was primarily due to a decrease in product sales due to the transition of sales from a distributor to direct to consumer of $127,761 and the discontinuation of hemp product sales of $27,194, an increase in product testing of $7,491, an increase in inventory shrinkage and obsolescence of $41,587, an increase in other manufacturing expenses of $13,702, and a decrease in payroll and employee benefit expenses of approximately $95,184 .

 

Gross profit

 

Gross profit for the nine months ended September 30, 2026 was $3,042,238 compared to $2,813,211 for the nine months ended September 30, 2025 representing an increase of 8%. This increase of $229,027 was primarily due to the increase in the demand from our direct-to-consumer sales channel of $107,342 an increase in contract manufacturing sales of $50,646, and a decrease in hemp derived product sales of $114,272 which was discontinued as of March 31, 2026, decrease in product sales due to the transition of sales from a distributor to direct to consumer of $127,761 and the discontinuation of hemp product sales of $27,194, an increase in product testing of $7,491, an increase in inventory shrinkage and obsolescence of $41,587, an increase in other manufacturing expenses of $13,702, and a decrease in payroll and employee benefit expenses of approximately $95,184.

 

Sales and marketing expenses

 

Sales and marketing expenses for the nine months ended September 30, 2026, were $802,721 compared to $462,545 for the nine months ended September 30, 2025, representing an increase of approximately 74%. This increase of $340,176 was primarily due to an increase in Amazon referral fees of $269,249, an increase in MPG fees of $135,749, an increase in advertising and promotional expenses of $28,202, an increase in professional fees $10,444, an increase in conference expenses of $9,023, and a decrease in payroll and employee benefit expenses of $111,950.

 

29

 

 

General and administrative expenses

 

General and administrative expenses for the nine months ended September 30, 2026 were $4,557,482 compared to $2,616,489 for the nine months ended September 30, 2025, representing an increase of approximately 74%. This increase of $1,940,993 was primarily attributable to an increase in payroll and employee benefit expenses of approximately $662,565, an increase in Amazon seller fees of approximately $214,300, an increase in insurance premiums of $155,805, an increase in public company related expenses of $157,544, an increase in professional fees of $910,542 increase in computer licenses and dues and subscriptions of $34,140, a decrease in settlement expenses of $50,629.

 

Other income / (expenses)

 

Other income /(expenses) for the nine months ended September 30, 2026 and 2025 was $8,017,827 compared to $171,986 representing a decrease of 4762%. This decrease of $8,189,813 was primarily due to a decrease in other income which was the result of an Employee Retention Tax Credit (“ERTC”) reimbursement of $419,947, decrease in interest income received of $64,931 which was primarily due to the ERTC, a loss on issuance of preferred stock of $6,310,464, a change of fair value of derivative liability of $1,097,362, an increase in other expense of $50,000, loss on issuance of preferred stock of $198,705 and an increase in interest expense of $48,353.

 

Liquidity and Capital Resources

 

Sources and Uses of Cash for the Nine Months ended September 30, 2026 and 2025

 

The table below, for the periods indicated, provides selected cash flow information:

 

    Nine months
Ended
September 30,
2026
    Nine months
Ended
September 30,
2025
 
Net cash (used in) provided by operating activities   $ (1,018,212 )   $ 1,478,358  
Net cash used in investing activities     -       (8,512 )
Net cash used in financing activities     (1,476,584 )     (676,164 )
Net increase (decrease) in cash   $ (2,494,796 )   $ 793,682  

 

Source of cash

 

Cash Flows from Operating Activities

 

During the nine months ended September 30, 2026, we used $1,018,212 in operating activities as a result of our net loss of $10,335,792, an increase of $304,467 in amortization of right-of-use and intangible assets, $437,973 in stock-based compensation, a change in fair value of derivative liabilities of $1,097,362, loss on issuance of preferred stock of $6,310,464, loss on default of convertible debentures of $198,705, dividends of $77,050, and net changes in operating assets and liabilities of $1,034,245.

 

During the nine months ended September 30, 2025, our operating activities provided $1,478,358 of cash as a result of our net loss of $93,837, offset primarily by $281,108 in amortization of right-of-use and intangible assets, $598,856 in stock-based compensation, issuance of shares and warrants of $95,893, and net changes in operating assets and liabilities of $571,249.

 

30

 

 

Cash Flows from Investing Activities

 

During the nine months ended September 30, 2026 and 2025, our investing activities was $0 and $8,512 respectively. In 2025 we used $8,512 in investing activities related to the purchase of property and equipment

 

Cash Flows from Financing Activities

 

During the nine months ended September 30, 2026, our financing activities used $1,476,584 of cash proceeds resulting primarily from $450,000 in repayment of liability conditional timing, $32,707 in loan proceeds, $329,002 in repayment of loans, $114,262 in dividend paid, and $616,027 for buyback of series A preferred shares,

 

During the nine months ended September 30, 2025, our financing activities used $676,164 of cash proceeds resulting primarily of deferred offering costs of $667,810, proceeds from loans and line of credit of $295,012, repayment of loans for $188,366, and payments for payable for acquisition of $115,000.

 

Letter of Intent

 

On May 11, 2026, we entered into a binding letter of intent with BullionFx regarding a proposed acquisition of certain intellectual property and related assets.

 

Under the terms of such letter of intent, the proposed consideration for the acquired assets is expected to consist of convertible preferred stock of the Company with an aggregate stated value of approximately $142.9 million, subject to independent third-party valuation and verification. The preferred stock was expected to automatically convert into shares of our common stock upon receipt of the required stockholder approval. Based on the capitalization assumptions set forth in the letter of intent, following the closing of the proposed transaction and prior to giving effect to any other equity financing, the current stockholders of the Company would own approximately 1.72% of the combined surviving company and the seller would own approximately 98.28% of the combined surviving company.

 

On June 29, 2026 we received a letter from BullionFX terminating the Letter of Intent.

 

Amendment

 

On May 11, 2026, the Company entered into a Conversion Price Reduction and Waiver Agreement with certain holders of the Company’s Series C Convertible Preferred Stock and related senior secured convertible promissory notes. Pursuant to the agreement, the conversion price applicable to the Series C Convertible Preferred Stock during the Fixed Conversion Period was amended to $0.1636 per share of common stock, replacing and superseding the previously applicable Tier 1, Tier 2 and Tier 3 fixed conversion prices and related tier allocation in their entirety.

 

In addition, pursuant to the agreement, any unpaid cash consideration under the applicable exchange documents as of the effective date of the agreement is to be added to and capitalized as additional principal under each applicable holder’s existing note.

 

Sources of Cash

 

On September 30, 2026, the Company entered into a loan agreement with a third party whereby the Company received approximately $32,707. The terms of the loan are for 10 months, with a 7.95% interest rate over the term of the loan.

 

On November 5, 2025 the Company entered into a loan agreement with a third party whereby the company received approximately $169,048. The terms of the loan are for 10 months, with a 7.0% interest rate over the term of the loan.

 

On November 4, 2025, Functional Brands Inc. completed a private placement to six institutional investors for gross proceeds of $8,000,000, and net of commissions the Company received proceeds of approximately $7,360,000. In exchange the investors were issued a total of 100,000 Series A preferred shares and 80,000 Series B preferred shares

 

On August 29, 2025 the Company entered into a loan agreement with a third party whereby the Company received approximately $95,277. The terms of the loan were for 10 months, with a 7.5% interest rate over the term of the loan.

 

On August 21, 2025, the Company entered into two lines of credit agreements with a third-party whereby the Company received a total of $26,354. The term of the loans were for six months, with a 9% contract interest rate. The loans are to be repaid in Feb 2026.

 

31

 

 

On April 29, 2025, the Company entered into a loan agreement with a third-party whereby the Company received $100,000. The term of the loan is for 1 year with a 22.95% finance charge.

 

On March 10, 2025, the Company executed a loan agreement with a related party in the amount of $225,000, with an annual interest rate of 18% and a due date of March 7, 2029.

 

During the nine months ended September 30, 2025 the Company entered into multiple lines of credit agreements with third parties to finance invoices to satisfy multiple vendors of which were repaid during the nine months ended September 30, 2026.

 

On June 18, 2024, the Company executed a loan agreement with a lender in the amount of $150,000. The payment terms are 12.5% OID, initial principal amount consisting of a $150,000 loan plus $21,500 OID totaling $171,500. In addition, the loan required the Company to issue 37,500 warrants with anti-dilution protection as well as an equity interest in the amount of 2,045 shares of the Company’s stock with reverse split protection through the Senior Exchange Listing. Loan is to mature the earlier of six months from execution, completion of a senior exchange listing of the Company or as mutually agreed, with an interest rate of the higher of 12% or WSJ Prime plus 4% guaranteed.

 

On March 11, 2024, the Company executed a loan agreement with a related party in the amount of $130,000, with an annual interest rate of 20% and a due date of March 11, 2031.

 

Critical Accounting Policies and Estimates

 

Our management’s discussion and analysis of our financial condition and results of operations is based on our unaudited condensed consolidated financial statements and accompanying notes included in this Quarterly Report on Form 10-Q, which have been prepared in accordance with accounting principles generally accepted in the United States. Preparing these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures. These estimates involve values or conditions that cannot be known with certainty when the financial statements are prepared. Management evaluates its estimates on an ongoing basis, based on historical experience, consultation with experts, and other methods it considers reasonable in the circumstances, as well as its forecasts of how those circumstances may change. Actual results could differ materially from these estimates. 

 

The judgements made in applying accounting policies that have the most significant effect on the amounts recognized in the consolidated financial statements include:

 

● Obsolescence of inventories;

 

● Recoverability of the carrying value of long-lived assets including property and equipment, and intangible assets;

 

● Recoverability of carrying value of goodwill;

 

● Discount rate used to calculate present value of future minimum lease payments for right-of-use asset and liabilities;

 

● Recognition and measurement of provisions and contingencies; and

 

● Valuation of deferred income tax assets.

 

Inventories, net

 

The Company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions, including forecasted demand compared to quantities on hand, as well as other factors such as potential excess or aged inventories based on product shelf life, and other factors that affect inventory obsolescence. As of December 31, 2025, the inventory reserve was $10,972.

 

As of September 30, 2026, the allowance for inventory obsolescence decreased $8,765 resulting in a reserve of $2,207

 

32

 

 

Long-Lived Assets

 

Long-lived assets consist primarily of property and equipment. Long-lived assets are tested for impairment when events and circumstances indicate the assets might be impaired by first comparing the estimated future undiscounted cash flows of the asset or asset group to the carrying value. If the carrying value exceeds the estimated future undiscounted cash flows, an impairment loss is recognized based on the amount that the carrying value exceeds the fair value of the asset or asset group. The Company did not recognize impairment losses during the nine months ended September 30, 2026, and 2025.

 

Fair Value of Financial Instruments

 

The Company determines the fair value of financial assets and liabilities using the fair value hierarchy established in Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurement (“ASC 820”). ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. The hierarchy describes three levels of inputs that may be used to measure fair value, as follows:

 

● Level 1 — Observable inputs, such as quoted prices in active markets for identical assets and liabilities.

 

● Level 2 — Observable inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

 

Application within the Company’s Financial Statements

 

The Company’s financial instruments consist primarily of cash, accounts receivable, accounts payable, accrued liabilities, related-party loans, line of credit, government loans, loans payable, convertible debentures (prior to conversion), and warrants issued in connection with financing arrangements. Management believes that, unless otherwise noted, the carrying amounts of these instruments approximate their fair values due to their short-term nature or because they bear interest at market rates.

 

The following items required fair value measurement or valuation analysis during the periods presented:

 

● Convertible Debenture

 

● Warrants Issued in Financing Transactions

 

● Equity Instruments Issued for Services and Financing

 

● Business Combination and Intangible Assets (Historical)

 

● Financial Instruments Carried at Amortized Cost

 

During the three and nine months ended September 30, 2026, the Company primarily applied fair value measurement to equity-linked financing instruments (warrants and stock issued for services), and historically, to convertible debt and business combination accounting. The majority of the Company’s remaining financial instruments are short-term or bear market-rate interest and therefore approximate fair value.

 

Derivative liabilities

 

Accounting for Convertible Preferred Stock and Embedded Derivative Liabilities

 

The Company issued Series A and Series B convertible preferred stock that contain complex conversion features. The accounting for these instruments requires significant judgment in the application of U.S. GAAP, including ASC 480 – Distinguishing Liabilities from Equity, ASC 815 – Derivatives and Hedging, and ASC 820 – Fair Value Measurement. Management evaluates the contractual terms of these instruments to determine the appropriate classification and measurement of the preferred stock and any embedded features.

 

33

 

 

Classification of Preferred Stock

 

Management evaluates whether preferred stock instruments should be classified as liabilities or equity under ASC 480. Instruments are classified as liabilities if they are mandatorily redeemable, require the issuer to repurchase shares by transferring assets, or obligate the issuer to issue a variable number of shares with a fixed or predominantly fixed monetary value.

 

The Company’s Series A and Series B preferred stock do not contain mandatory redemption provisions, holder put rights, or other obligations requiring the Company to transfer cash or other assets to the holders. Accordingly, management concluded that the preferred stock represents equity instruments and the host contracts are classified within stockholders’ equity.

 

Embedded Conversion Features

 

The preferred stock includes conversion features that allow holders to convert the preferred shares into common stock at variable conversion prices that are subject to market-based adjustments, reset provisions, and anti-dilution protections.

 

Management evaluates these features under ASC 815 to determine whether they must be separated from the host instrument and accounted for as derivatives. This assessment requires judgment regarding whether the features:

 

● Meet the definition of a derivative under ASC 815

 

● Are clearly and closely related to the host contract

 

● Qualify for equity classification under ASC 815-40

 

The Company concluded that the embedded conversion features meet the definition of derivatives because they are based on the Company’s stock price, involve a notional amount representing the shares issuable upon conversion, require minimal initial investment, and permit net settlement through the issuance of publicly traded shares.

 

Management further concluded that the conversion features are not clearly and closely related to the equity host instrument and do not qualify for equity classification because the variable conversion pricing and reset mechanisms cause the features to fail the “indexed to the Company’s own stock” requirement under ASC 815-40. Accordingly, the embedded conversion features are bifurcated and recorded separately as derivative liabilities.

 

Initial Measurement and Allocation of Proceeds

 

At issuance, the derivative liabilities are measured at fair value. The Company determined the fair value of the embedded conversion features using a Monte Carlo simulation model, which incorporates assumptions regarding expected stock price volatility, expected term, risk-free interest rates, and the impact of contractual reset and floor provisions.

 

The proceeds received from the issuance of the preferred stock are allocated between the derivative liability and the preferred stock host instrument using the residual method. Under this method, the derivative liability is recorded at fair value and the remaining amount of the proceeds is allocated to the preferred stock. Because the stated value of the preferred shares exceeds the amount allocated to the host instrument, the Company records the difference as a contra-equity discount within stockholders’ equity.

 

Subsequent Measurement

 

After initial recognition, the derivative liabilities are remeasured at fair value at each reporting date, with changes in fair value recognized in the consolidated statements of operations. The preferred stock host instrument remains classified within equity and is not subsequently remeasured.

 

Upon conversion of preferred shares into common stock, the Company derecognizes the associated portion of the derivative liability and adjusts the related equity discount accordingly.

 

34

 

 

Fair Value Measurements and Significant Estimates

 

The valuation of the derivative liabilities involves the use of significant unobservable inputs and requires substantial management judgment. Key assumptions used in the valuation model include:

 

● Expected volatility of the Company’s common stock

 

● Expected term of the instruments

 

● Risk-free interest rates

 

● Expected conversion behavior and the impact of contractual reset provisions

 

Because these assumptions are not directly observable in the market, the derivative liabilities are classified as Level 3 measurements within the fair value hierarchy under ASC 820.

 

Changes in these assumptions or market conditions could materially affect the estimated fair value of the derivative liabilities and result in significant non-cash gains or losses in future reporting periods.

 

Segment Reporting

 

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires entities to report incremental information about significant segment expenses included in a segment’s profit or loss measure as well as the title and position of the chief operating decision maker (“CODM”). The new standard also requires interim disclosures related to reportable segment profit or loss and assets that had previously only been disclosed annually. The Company adopted ASU 2023-07 effective December 31, 2024 on a retrospective basis.

 

Income taxes

 

The Company must exercise judgment in determining the provision for income taxes. There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. The Company recognizes liabilities and contingencies for expected tax audit issues based on the Company’s current understanding of the tax law. For matters where it is probable that an adjustment will be made, the Company records its best estimate of the tax liability including the related interest and penalties in the current tax provision.

 

In addition, the Company recognizes deferred tax assets relating to tax losses carried forward to the extent there are sufficient taxable temporary differences (deferred tax liabilities) relating to the same taxation authority and the same taxable entity against which the unused tax losses can be utilized. However, utilization of the tax losses also depends on the ability of the taxable entity to satisfy certain tests at the time the losses are recouped.

 

Events of Default under the Series C Convertible Preferred Shares and Senior Secured Convertible Notes

 

Overview

 

During the quarter ended September 30, 2026, the Company was in default under its Series C Convertible Preferred Shares (the “Series C”) and its Senior Secured Convertible Notes (the “Notes”), each issued in the March 9, 2026 exchange transaction. The events of default arose from two independent causes: the Company’s failure to commence the mandatory redemption of the Series C, effective June 8, 2026, and the loss of the Company’s Nasdaq listing on June 16, 2026. The effects of the events of default are reflected in the accompanying financial statements.

 

Conversion price reduction (May 2026)

 

On May 11, 2026 — prior to the events of default — the Company entered into a Conversion Price Reduction and Waiver Agreement with certain holders of the Series C and the Notes. The agreement reduced the conversion price applicable to the Series C during the fixed conversion period to $0.1636 per share, superseding the previously applicable tiered fixed conversion prices in their entirety, and provided that any unpaid cash consideration under the exchange documents would be capitalized as additional principal under the applicable holders’ Notes. During the quarter, holders converted Series C with an aggregate stated value of $3,268,000 into common stock at the reduced conversion price, reducing the outstanding stated value of the Series C to $2,764,000 at September 30, 2026 and increasing the number of common shares outstanding.

 

35

 

 

Mandatory redemption

 

The Series C is subject to a mandatory redemption (forced amortization) provision requiring the Company to begin redeeming the Series C in equal monthly installments of $230,333 beginning on or about June 8, 2026, payable at the Company’s election in cash monthly or in shares of common stock weekly, subject in the case of share settlement to satisfaction of the applicable equity conditions. The Company did not commence the mandatory redemption and made no redemption installment during the quarter or through the date of this report. The Company concluded that this failure constitutes an event of default, effective June 8, 2026. The company has not undertaken mandatory redemption as of September 30, 2026.

 

Loss of Nasdaq listing

 

On June 16, 2026, the Company’s common stock ceased trading on the Nasdaq Capital Market and began trading in the over-the-counter market, following a Nasdaq staff delisting determination issued June 8, 2026. The failure to maintain a listing on a national securities exchange constitutes a separate and independent event of default under the Notes.

 

Effect on the Company’s obligations

 

As a result of the events of default, and effective from the applicable event-of-default date: the dividend rate on the Series C increased from 0% to 24% per annum, recognized as interest expense; the outstanding obligations under the Notes increased to 125% of the amounts otherwise outstanding under the default-premium provisions; interest on the Notes accrues at the 24% default rate; the Company became obligated for a monthly monitoring fee of $5,000; and the conversion price applicable to the Series C and the Notes became the alternate conversion price (85% of the lowest trading price over a ten-trading-day lookback), which increases the number of common shares issuable on conversion and the resulting potential dilution to existing stockholders. Because the events of default give the holders the right to accelerate repayment, the Notes, which were otherwise scheduled to begin amortizing more than twelve months after the balance sheet date, have been reclassified from long-term to current liabilities as of September 30, 2026. The outstanding stated value of the Series C is likewise classified as a current liability.

 

Impact on results of operations

 

For the three months ended September 30, 2026, the Company recognized a loss of $714,455 on the change in fair value of its embedded conversion derivative liabilities (a loss of $942,568 for the nine months ended September 30, 2026, reflecting a fair-value gain in the first quarter), included in other income (expense), net. In connection with the events of default, the Company also recognized default-rate interest expense on the Series C and the Notes, a default premium reflecting the increase in the Note obligations to 125%, and monitoring fees. For the nine months ended September 30, 2026, other expense also included a loss of $6,310,464 on the issuance of preferred stock in the March 2026 exchange. General and administrative expenses increased approximately 15% over the prior-year quarter, driven principally by higher payroll, professional fees, and marketplace selling fees. The Company reported a net loss of $10,335,792 for the nine months ended September 30, 2026.

 

Liquidity and capital resources

 

At September 30, 2026, the Company had cash of $231,900 and a working capital deficit of $5,804,557, and used $1,018,212 of cash in operating activities during the nine months then ended. The events of default, the resulting acceleration rights and reclassification of the Notes to current liabilities, the mandatory redemption of the remaining $2,764,000 of Series C stated value, and the increased default-rate interest and premium each exceed the Company’s available cash and cash generated from operations, and the Company does not currently have committed financing sufficient to satisfy these obligations as they come due. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to settle redemption and amortization obligations in shares of common stock is constrained by the failure of the applicable equity conditions following the events of default and by limitations on issuances that would require stockholder approval; to the extent obligations are settled in shares at the alternate conversion price, existing stockholders would experience substantial dilution. The Company is in discussions with the holders regarding the terms of the instruments and is evaluating available alternatives, which may include waivers, forbearance, or amendments, restructuring or refinancing, and raising additional capital. As of the date of this report, no holder had accelerated the Notes or the Series C. There can be no assurance that any such alternative will be available on acceptable terms, or at all. See the notes to the financial statements for additional information regarding the events of default and the Company’s going-concern assessment.

 

36

 

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

 

We are a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act, and as a result are not required to provide the information required by this Item.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

 

Evaluation of Disclosure Controls and Procedures

 

As required by Rules 13a-15 and 15d-15 under the Exchange Act, our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2026. Based upon their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15 (e) and 15d-15 (e) under the Exchange Act) were not effective due to the existence of the material weaknesses in the Company’s internal control over financial reporting.

 

Notwithstanding the conclusion by our Chief Executive Officer and Chief Financial Officer that our disclosure controls and procedures as of September 30, 2026 were not effective, and notwithstanding material weaknesses in our internal control over financial reporting, management believes that the unaudited consolidated financial statements and related financial information included in this Report fairly present in all material respects our financial condition, results of operations and cash flows as of the dates presented, and for the periods ended on such dates, in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”).

 

Changes in Internal Control over Financial Reporting

 

There have been no changes in our internal control over financial reporting during the quarter ended September 30, 2026 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.

 

37

 

 

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

 

Trailer Park Boys

 

On November 13, 2025, Trailer Park Boys Inc. (“TPB”) commenced a civil claim against the Company and certain other defendants alleging breach of contract. On February 27, 2026, the Company filed a Statement of Defense denying the allegations advanced by TPB. The Company has also filed a Statement of Counterclaim against TPB asserting claims for breach of contract and negligent misrepresentation in connection with the same agreement. The litigation is at an early stage. The Company intends to vigorously defend the TPB claim and pursue its counterclaim.

 

True Health

 

On May 25, 2021, True Health Medical Center, S.C. (“True Health”) amended an existing complaint against Kirkman Group, Inc. (“Kirkman”), James Hall and David Humphrey to assert claims against HTO Nevada, Inc. and HTO Holdings, Inc. (collectively, HTO Nevada, Inc. and HTO Holdings, Inc. are referred to as the “HTO Parties”). Kirkman was the seller of certain assets to the HTO Parties and is a separate legal entity. Affiliates of the HTO Parties were first named in the lawsuit on September 23, 2020.

 

On July 14, 2026, the Circuit Court for the Eighteenth Judicial Circuit, DuPage County, Illinois entered a final order and judgment following a bench trial in the previously disclosed litigation brought by True Health Medical Center, S.C. (“True Health”) against Kirkman Group, Inc. (“Kirkman”), certain individuals, and the HTO Parties. The court entered judgment in favor of the HTO Parties on all counts asserted against them, finding that no royalties are due or owing from the HTO Parties under the royalty agreement. The court determined that the reformulated “981” product is a different product from the “881” product covered by the royalty agreement, and accordingly that no ongoing royalty obligation exists with respect to the 981 product. The court entered judgment against Kirkman, the seller of certain assets to the HTO Parties and a separate legal entity, in the amount of $68,271, consisting of $41,683 in unpaid royalties on sales of the 881 product for the period December 2018 through June 2019 and $26,588 in interest. All claims against the individual defendants were resolved in favor of those defendants, and the case was closed. The time to appeal has not expired, and any party may seek to appeal the judgment. Because no amounts were awarded against the HTO Parties, the Company has not recorded any liability with respect to this matter in the accompanying condensed consolidated financial statements.

 

Item 1A. Risk Factors

 

Other than as set forth below, as of the date of this Quarterly Report there have been no material changes with respect to those risk factors previously disclosed in our Annual Report on Form 10-K filed with the SEC. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations.

 

Our common stock is no longer listed on a national securities exchange and is quoted on the OTC Markets, which may adversely affect the liquidity and market price of our common stock and our ability to raise capital.

 

Our common stock was removed from listing on The Nasdaq Stock Market and is currently traded on OTC Markets Group Inc. Securities quoted on the OTC Markets generally experience lower trading volumes, wider bid-ask spreads, greater price volatility and less consistent price discovery than securities listed on a national securities exchange. Quotation is dependent on the continued willingness of one or more market makers to publish quotations, and there is no assurance that an active trading market for our common stock will be maintained. Certain institutional investors, mutual funds and other market participants are subject to internal or contractual policies that prohibit or limit investment in securities that are not exchange-listed, and our common stock is no longer eligible for inclusion in indices that require exchange listing. In addition, our common stock may not be eligible for margin lending under Regulation T. Any of the foregoing may reduce demand for our common stock, depress its market price, and make it more difficult and more expensive for us to raise capital or to use our common stock as consideration in acquisitions or in settlement of obligations. These effects may be more pronounced given the substantial doubt about our ability to continue as a going concern described in Note 2 to our condensed consolidated financial statements.

 

38

 

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

(a) Unregistered Sales of Equity Securities

 

See Note 18 in the footnotes to the financial statements.

 

(b) Not applicable.

 

(c) Issuer purchases of equity securities: None.

 

Item 3. Default Upon Senior Securities

 

Series C mandatory redemption. The Company’s Series C Convertible Preferred Shares (the “Series C”), issued March 9, 2026 and accounted for as a debt host instrument with a bifurcated embedded conversion derivative, are subject to a mandatory redemption provision requiring the Company to begin redeeming the Series C in equal monthly installments beginning on or about June 8, 2026. The Company did not commence the mandatory redemption and made no redemption installment during the three months ended September 30, 2026. The Company has concluded that its failure to commence the mandatory redemption constitutes an Event of Default under the Series C and the Company’s Senior Secured Convertible Notes (the “Notes”), with an event-of-default date of June 8, 2026.

 

Concurrent listing event of default. Separately, on June 16, 2026 the Company’s common stock ceased trading on the Nasdaq Capital Market and began trading in the over-the-counter market, following a Nasdaq staff delisting determination. The failure to maintain a listing on a national securities exchange constitutes a separate and independent Event of Default under the Notes.

 

Effect on the instruments. As a result of the Events of Default, and from the applicable event-of-default date: (i) the dividend rate on the Series C increased from 0% to 24% per annum, which, given the debt classification of the Series C, the Company recognizes as interest expense; (ii) the outstanding obligations under the Notes increased to 125% of the amounts otherwise outstanding under the default-premium provisions; (iii) interest on the Notes accrues at the 24% default rate; (iv) the Company became obligated for a monthly monitoring fee of $5,000; and (v) the conversion price applicable to the Series C and the Notes became the alternate conversion price (85% of the lowest trading price over a ten-trading-day lookback), which the Company reflected in the remeasurement of the embedded conversion derivatives at September 30, 2026.

 

Remedies and status. The Events of Default afford the holders various rights and remedies, including the right to accelerate the Notes and to exercise the default remedies described above. As of the date of this report, no holder had accelerated the Notes or the Series C. The Company is in discussions with the holders.

 

Item 4. Mine Safety Disclosures

 

None.

 

Item 5. Other Information

 

Adoption or Termination of Rule 10b5-1 or non-Rule 10b5-1 Trading Arrangements

 

During the quarter ended September 30, 2026, no director or officer adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

 

39

 

 

Item 6. Exhibits

 

The following exhibits (listed by number corresponding to the Exhibit Table as Item 601 in Regulation S-K) are filed with this report:

 

EXHIBIT INDEX

 

Exhibit No.   Description
3.1   Form (Revised) of Certificate of Designation, Preferences and Rights of the Series A Convertible Preferred Share (incorporated by reference to Exhibit 3.8 to the Registration Statement on Form S-1 filed with the SEC on October 16, 2025)
3.2   Form (Revised) of Certificate of Designation, Preferences and Rights of the Series B Convertible Preferred Share (incorporated by reference to Exhibit 3.9 to the Registration Statement on Form S-1 filed with the SEC on October 16, 2025)
10.1   Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.23 to the Registration Statement on Form S-1 filed with the SEC on October 16, 2025)
10.2   Form of Amendment to Securities Purchase Agreement (incorporated by reference to Exhibit 10.29 to the Registration Statement on Form S-1 filed with the SEC on October 16, 2025)
10.3   Escrow Agreement, dated August 6, 2025 (incorporated by reference to Exhibit 10.26 to the Registration Statement on Form S-1 filed with the SEC on October 16, 2025)
10.4   Eighth Amended Forbearance (incorporated by reference to Exhibit 10.28 to the Registration Statement on Form S-1 filed with the SEC on October 16, 2025)
10.5   Ninth Amended Forbearance (incorporated by reference to Exhibit 10.30 to the Registration Statement on Form S-1 filed with the SEC on October 16, 2025)
10.6   Marketing Services Agreement, dated July 23, 2025, between the Company and Outside The Box Capital Inc. (incorporated by reference to Exhibit 10.25 to the Registration Statement on Form S-1 filed with the SEC on October 16, 2025)
31.1*   Certification of Chief Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*   Certification of Chief Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**   Certificate of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**   Certificate of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith
** Furnished herewith.

 

40

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  Functional Brands Inc.
   
Date: November 16, 2026 By: /s/ Eric Gripentrog
  Name: Eric Gripentrog
  Title: Chief Executive Officer
    (Principal Executive Officer)
     
Date: November 16, 2026 By: /s/ David R Wells
  Name:  David R. Wells
  Title: Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

 

41

 

 

Keep reading